#105 – Bringing Positive Vibes Only: Breaking News & Emerging Hypotheses for Gram-Positive Bacterial Infections Oct 25, 2024

Drs. Cesar Arias (@SuperBugDoc) and Katie Barber join Dr. Julie Ann Justo (@julie_justo) to discuss what is hot-off-the-presses for gram-positive bacterial infections and it’s a total party vibe! They review the latest news for recent and ongoing clinical trials (DOTS, DISRUPT, and SNAP trials), discuss hope for novel clinical tests of the cefazolin inoculum effect in staphylococci, and explore the fascinating changes in virulence and potential therapeutic options for the most challenging enterococci.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp

References

Climate Change and Antimicrobial Resistance. Editors in Conversation Podcast. American Society for Microbiology. Oct 2023.
Is More Better? The Role of Combination Therapy for MRSA. Breakpoints Podcast Episode #30. Society of Infectious Diseases Pharmacists.
Turner NA, et al. DOTS: Dalbavancin as an Option for Treatment of Staphylococcus aureus Bacteremia. ESCMID Global 2024. April 2024. NCT04775953.
Real-world dalbavancin observational cohort: Rebold N, et al. Infect Dis Ther. 2024 Mar;13(3):565-579. doi: 10.1007/s40121-024-00933-2. PMID: 38427289.
Exebacase DISRUPT trial : Fowler VG Jr, et al. Clin Infect Dis. 2024 Jun 14;78(6):1473-1481. doi: 10.1093/cid/ciae043. PMID: 38297916.
@snap_trial tweet of Breaking News. Aug 2024.
Investigator Resources for the SNAP trial. Sept 2024: https://www.snaptrial.com.au/for-investigators#interim
Cefazolin inoculum effect on mortality in MSSA bacteremia : Miller WR, et al. Open Forum Infect Dis. 2018 May 23;5(6):ofy123. doi: 10.1093/ofid/ofy123. PMID: 29977970.
Prevalence of cefazolin inoculum effect in MSSA and modified rapid nitrocefin test for detection: Carvajal LP, et al. Antimicrob Agents Chemother. 2024 Sep 30:e0089824. doi: 10.1128/aac.00898-24. PMID: 39345182.
LiaX as surrogate for cell envelope stress in Enterococus faecium: Axell-House DB, et al. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0106923. doi: 10.1128/aac.01069-23. PMID: 38289081.
Shorter is better for uncomplicated streptococcal bacteremia: Clutter DS, et al. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0022024. doi: 10.1128/aac.00220-24. PMID: 38975753.
Short vs. long antibiotic duration in Streptococcus pneumoniae bacteremia: Crotty M, et al. Open Forum Infect Dis. 2024 Aug 30;11(9):ofae478. doi: 10.1093/ofid/ofae478. PMID: 39257675.

This podcast is powered by Pinecast.

#104 – Dosing Consult: Rifampin Part 1 Oct 04, 2024

In this episode of Breakpoints’ Dosing Consult series, Drs. Chuck Peloquin and Gerry Davies join Dr. Megan Klatt to discuss rifampin dosing for mycobacterial infections. Hear from the experts on if higher doses are really better, toxicity thresholds, and the role of alternative rifamycins for patients with MTB and NTMs.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp

References:

Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 Sep 1;198(5):657-666. doi: 10.1164/rccm.201712-2524OC.
Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027-1036. doi: 10.1080/17512433.2017.1366311.
Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2007 Oct; 2007(4): CD005159. doi: 10.1002/14651858.CD005159.pub2.
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease. Clin Infect Dis. 2023 Oct 5;77(7):1053-1062. doi: 10.1093/cid/ciad312.

This podcast is powered by Pinecast.

#103 – Dosing Consult: Daptomycin Sep 06, 2024

Drs. Jim Rhodes and Molly Steed join host Jeannette Bouchard to discuss all things related to optimal dosing of daptomycin. This podcast episode provides insight on why dosing matters with this antibiotic, especially with certain organisms (looking at you, E. faecium), why weight matters with dosing, and what that pesky CPK means.

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

References:

Fixed-dose daptomycin in Staphylococcus aureus: doi 10.1002/phar.4602
High dose daptomycin for VRE: doi 10.1093/cid/ciw815

This podcast is powered by Pinecast.

#102 – Oh, the Places Stewardship Will Go! Best Practices for Outpatient Antibiotic Stewardship and Transitions of Care Aug 23, 2024

In this episode, Drs. Erica Stohs, Ryan Stevens, and Jame McCrae join Dr. Megan Klatt to discuss antimicrobial stewardship practices at transitions of care and in the outpatient setting. Hear from the experts on how to establish programs in this space, best practices for data/reporting, and other tips for stewardship intervention.

Follow us on Instagram! @breakpointspodcast_sidp

References:

Pharmacist-Driven Transitions of Care Practice Model for Prescribing Oral Antimicrobials at Hospital Discharge. 10.1001/jamanetworkopen.2022.11331
From concept to reality: Building an ambulatory antimicrobial stewardship program. 10.1002/jac5.1528
Cracking the code(s): Optimization of encounter-level diagnosis coding to inform outpatient antimicrobial stewardship data modeling. 10.1017/ice.2023.296
Antibiotic Prescribing Variability in a Large Urgent Care Network: A New Target for Outpatient Stewardship. 10.1093/cid/ciz910
DART communication for respiratory illness treatment resources: Dialogue Around Respiratory Illness Treatment (DART) – iMTR (uwimtr.org)

#101 – BLING III: Does Continuous Infusion Make the Whole Place Shimmer Aug 02, 2024

Join Prof Jason Roberts and Dr. Erin McCreary for this episode dedicated to discussing the results of the BLING III trial, which explored the use of continuous versus intermittent infusion of a beta-lactam antibiotic in critically ill patients.

Reference: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. 10.1001/jama.2024.9779

#100 – Tackling Tetracyclines: Breakpoints 100th Episode! Jul 26, 2024

Drs. Jeffrey Pearson and Jason Pogue join Dr. Jeannette Bouchard as they take on all things tetracyclines. Starting with tetracycline, they walk through differences between each generation and drug in this class, from dosing all the way to pertinent resistance mechanisms. You will not want to miss out on this one! This podcast was supported by an unrestricted grant from Paratek Pharmaceuticals Inc.

References:

Omadacycline for Mycobacterium abscessus full case series data set: 10.1128/aac.00824-23
Long term safety of omadacycline in Mycobacterium abscessus: 10.1093/ofid/ofad335
USCAST Acinetobacter baumannii Recommendations for Susceptibility Test Interpretive Criteria: https://www.uscast.org/uploads/1/1/9/0/119044870/uscast_alepak_acbc_stic_08feb23.pdf

#99 – Don’t be CRABby: Acinetobacter baumannii review Jun 28, 2024

Drs. Yohei Doi and Emily Heil join Dr. Erin McCreary to dive into one of the most requested topics from our listeners and something that is consistently confusing in clinical practice: Acinetobacter baumannii! Hear from experts on their experience with treating this tricky organism and their thoughts on best approaches when you are presented with CRAB. Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

References:

SNAP doi:10.1128/mbio.02759-2
ATTACK doi:10.1016/S1473-3099(23)00184-6
CRAB among COVID patients: doi:10.1093/jac/dkad042

#98 – Uncomplicated UTIs: Getting Uncomfortable with Uncertainty May 24, 2024

Drs. Chris Crnich, Angela Huttner, and Jeannette Bouchard join Dr. Erin McCreary to discuss all things uncomplicated UTIs! Gain insight into where our new guidelines may be headed and pearls from experts in a variety of clinical settings, including a clinic specifically devoted to UTIs! Funding for this podcast was supported by an independent medical education grant from GSK.

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

References:

Proposing the "Continuum of UTI" doi: 10.1097/JU.0000000000003874
UTIs exciting new frontier doi: 10.1016/j.cmi.2022.07.016
Fosfo vs Nitro doi: 10.1001/jama.2018.3627

#97 – Hot Topics: What Did You Miss in Infectious Diseases in 2023-2024 (LIVE from MAD-ID) May 17, 2024

In this special LIVE podcast episode, Drs. Emily Heil (@emilyheil) and Mandee Noval (@MandeeNoval) present the latest and greatest in ID literature from MAD-ID 2024 (@MAD_ID_ASP) in Orlando, FL. They cover everything from ECCMID late breakers to stewardship to the best things to come out of a good old shortage! You won’t want to miss this one!

Google Drive to Slides from Live Session: https://drive.google.com/file/d/1L4zq0ZC5LW9cCySE0AiJL7m8qDxS9MGM/view?usp=sharing

Submit your 100th Episode videos at: sidp@affinity-strategies.com

Check out more information on ID Pharmacists Day on May 22nd, 2024 at SIDP.org/IDPharmacistsDay

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

#96 – The Tortured Stewards & Surgeons Department Apr 19, 2024

Episode Notes

The Society of Infectious Diseases Pharmacists is excited to invite you to the first ever meeting (via Breakpoints) of The Tortured Stewards & Surgeons Department. Today’s agenda items: optimal management of perioperative antibiotics and prevention of surgical site infections.

Drs. Trisha Peel (@DrTrishaPeel), Michael Calderwood (@CalderwoodMD) and Patch Dellinger join Dr. Jillian Hayes (@thejillianhayes) to discuss some of the controversies we encounter while managing antibiotics in the perioperative space. Does anyone really need post-op antimicrobial prophylaxis longer than 24 hours? Where should vancomycin be fitting into surgical prophylaxis regimens? Can we truly give pre-operative cefazolin to patients with a penicillin allergy? Tune in for the answers to these questions and more!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp

If you’d like more information about the CALIPSO trial, please visit this link: https://www.anzca.edu.au/profiles/ctn-trials/underway/calipso

Bibliography

SSI Infection Prevention Review: https://jamanetwork.com/journals/jama/article-abstract/2800424#:~:text=Six%20are%20supported%20by%20randomized,use%20a%20chlorhexidine%20gluconate%2Dalcoho
Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update: https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/strategies-to-prevent-surgical-site-infections-in-acutecare-hospitals-2022-update/2F824B9ADD6066B29F89C8A2A127A9D
American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update: https://journals.lww.com/journalacs/citation/2017/01000/american_college_of_surgeons_and_surgical.8.aspx
2017 CDC Guidelines: https://jamanetwork.com/journals/jamasurgery/fullarticle/2623725
2018 WHO Guidelines: https://arthroplasty.biomedcentral.com/articles/10.1186/s42836-022-00113-y
ASHP Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery: https://www.ashp.org/surgical-guidelines
Surgeons as Stewards: https://journals.lww.com/journalacs/citation/2020/12000/perioperative_antibiotic_prophylaxis__surgeons_as.23.aspx
Li et al, Arthroplasty 2022: https://arthroplasty.biomedcentral.com/articles/10.1186/s42836-022-00113-y
Dutch Arthroplasty Register Study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023957/
de Jonge Meta-Analysis on duration and incidence of SSI: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30084-0/abstract
Prolonged Antibiotic Prophylaxis After Cardiovascular Surgery and Its Effect on Surgical Site Infections and Antimicrobial Resistance: https://www.ahajournals.org/doi/10.1161/01.cir.101.25.2916?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
RCT - Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: https://jamanetwork.com/journals/jama/article-abstract/2810510
NYU Langone Study - Preventing Surgical Site Infections: A Randomized, Open-Label Trial of Nasal Mupirocin Ointment and Nasal Povidone-Iodine Solution: https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=91dee3e1445adb80d533f2c210816a3285254e3a
Trial of Vancomycin and Cefazolin as Surgical Prophylaxis in Arthroplasty: https://www.nejm.org/doi/full/10.1056/NEJMoa2301401
What Is the Primary Driver of Preoperative Vancomycin Use? It’s Not Methicillin-resistant Staphylococcus aureus—or Allergy: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744972/
Drug allergy: a 2022 practice parameter update: https://www.jacionline.org/article/S0091-6749(22)01186-1/fulltext
Perioperative use of cefazolin without preliminary skin testing in patients with reported penicillin allergy: https://www.surgjournal.com/article/S0039-6060(18)30307-6/abstract#%20
Timing of Surgical Prophylaxis RCT: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30176-7/abstract
Propensity Score-Weighted Analysis of Postoperative Infection in Patients With and Without Preoperative Urine Culture: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2815528

#95 – A to Z on R&D: Challenges and Solutions for Sustained Antimicrobial Drug Development Mar 29, 2024

In this episode, Drs. Helen Boucher (@hboucher3), Ramy Elshaboury, and Mike Dudley (@MikeMNDudley) join host, Megan Klatt (@MeganKlatt3), to discuss barriers to antimicrobial drug development, potential incentives and legislation to promote market growth, and what we can do to ensure the antimicrobial pipeline doesn’t run dry.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp

References

An analysis of antibacterial drug development trends in the United States, 1980-2019: Dheman N, et al. Clin Infect Dis. 2021 Dec 6;73(11):e4444-e4450. doi:10.1093/cid/ciaa859. PMID: 32584952.
Antibacterial R&D at a crossroads: we’ve pushed as hard as we can…now we need to start pulling!: Rex JH, Outterson K. Clin Infect Dis. 2021 Dec 6;73(11):e4451-4453. doi:10.1093/cid/ciaa852. PMID: 32584949.
No Patient Left Behind (website): https://www.nopatientleftbehind.org/ (many useful explainers of how the investment, innovation cycle, and drug pricing work)
ISPOR special task force report on defining elements of value in health care – a health economics approach: Lakdawalla DN, et al. Value Health. 2018 2018 Feb;21(2):131-139. doi: 10.1016/j.jval.2017.12.007. PMID: 29477390.
Generalized cost-effectiveness analysis to assess treatment value in hepatitis C: Chou JW, et al. Am J Manag Care. 2023 Dec;29(12):696-703. doi: 10.37765/ajmc.2023.89468. PMID: 38170486.

#94 – Lock, Stock, & Sterilize: Strategies to Optimize Antimicrobial Lock Therapy & Prevent/Treat Catheter-Related Bloodstream Infections Mar 22, 2024

It's time to arm yourselves with all the resources on antimicrobial locks! Join our experts, Drs. Louise-Marie Oleksiuk (@CanRowPharm), Nasia Safdar (@NasiaSafdar), Joel Topf (@kidney_boy), and our wonderful host, Dr. Julie Justo (@julie_justo), to discuss the ins and outs of antimicrobial locks and how to implement them! Funding for this podcast was provided by CorMedix Inc

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp

References

https://drive.google.com/file/d/1K0A4Bomhbcn7AZJ1JFOWW8EdEZq-aZcd/view?usp=sharing
https://drive.google.com/file/d/1PRoQzEKJ1c0pa1XFc4yasxsMhx2A1DFU/view?usp=sharing
Helpful antimicrobial lock review: Justo JA, Bookstaver PB. Infect Drug Resist. 2014 Dec 12;7:343-63. doi: 10.2147/IDR.S51388. PMID: 25548523.
LOCK IT-100 Trial: Agarwal AK, et al. Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1446-1455. doi: 10.2215/CJN.0000000000000278. PMID: 37678222.
Cochrane review: Arechabala MC, et al. Cochrane Database Syst Rev. 2018 Apr 3;4(4):CD010597. doi: 10.1002/14651858.CD010597.pub2. PMID: 29611180.
Cost-effectiveness of ethanol lock ppx with newer dehydrated alcohol product: Raghu VK, et al. JPEN J Parenter Enteral Nutr. 2022 Feb;46(2):324-329. doi: 10.1002/jpen.2130. PMID: 33908050.
Antimicrobial lock development/implementation in a pediatric hospital: Zembles TN, et al. Am J Health Syst Pharm. 2018 Mar 1;75(5):299-303. doi: 10.2146/ajhp161056. PMID: 29472511.
Dr. Topf’s tweet surveying the prevalence of antimicrobial lock use in dialysis units
CRBSIs in hemodialysis patients before and during the COVID-19 pandemic: Johansen KL, et al. Clin J Am Soc Nephrol. 2022 Mar;17(3):429-433. doi: 10.2215/CJN.11360821. PMID: 35110377.
Antiseptic barrier caps review and meta-analysis: Gillis VELM, et al. Am J Infect Control. 2023 Jul;51(7):827-835. doi: 10.1016/j.ajic.2022.09.005. PMID: 36116679.

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#93 – Global, Live Journal Club: Ceftobiprole for Complicated Staphylococcus aureus Bacteremia (ERADICATE Study) Feb 23, 2024

Drs. Thomas Holland and Vance Fowler (@VanceFowler5) join Drs. Steven Tong (@syctong) and Erin McCreary (@ErinMcCreary) to discuss the ERADICATE study and the role of ceftobiprole for the treatment of complicated Staphylococcus aureus bacteremia. This session was recorded live on Tuesday, February 6th, 2024 featuring an international audience.

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2300220

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#92 – Antibiotic Alchemy: Metallo-Beta-Lactamases Feb 02, 2024

Drs. Robert Bonomo, Ryan Shields (@ryankshields), and Erin McCreary (@ErinMcCreary) deep dive into the world of metallo-beta-lactamases. This riveting discussion is full of the nerdiest pub trivia nuggets and the “must know” details of novel beta lactams and beta-lactamase inhibitors, and their uses for MBLs. Funding for this podcast was provided by Shionogi Inc.

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

References:

Urgent need for metallo B lactamase: DOI: 10.1016/S1473-3099(20)30868-9
NDM-9 Resistance to Taniborbactam: DOI 10.1016/S1473-3099(23)00069-5
AAC Taniborbactam inhibition of NDM-1: DOI 10.1128/aac.01332-23
OFID NDM E. coli with cefiderocol and aztreonam/avibactam resistance: DOI 10.1093/ofid/ofad276

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#91 – Teamwork Makes the Dream Work: Preparation Pearls for Stewardship and Microbiology Lab Accreditation Updates Jan 19, 2024

New accreditation standards making your head spin? Are you stressed and don’t know where to start? Well, on this episode of Breakpoints Drs. Arjun Srinivasan and Jose Alexander (Alex) join Luis Plaza from Let’s Talk Micro (@letstalkmicro1) and Dr. Jeannette Bouchard (@jlbouchard001) to breakdown what you need to know and where to start when it comes to the NHSN Antimicrobial Resistance (AR) module and the new College of American Pathologist’s standards. Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

References:

CDC AR Validation Guide: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/aur/ar-validation-508.pdf
CLSI Toolkit: https://clsi.org/meetings/ast/breakpoints-in-use-toolkit/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#90 – IDWeek 2023 Recap: Pipeline Agents and Clinical Trials That May Change Your Practice Jan 05, 2024

We are back with more exciting IDWeek 2023 content! If you listened to the last episode and want more? Than look no further.

Join your Breakpoints hosts, Drs. Erin McCreary (@ErinMcCreary), Julie Ann Justo (@julie_justo), and Jeannette Bouchard (@jlbouchard001) for a review of key pipeline agents at IDWeek and highlights from everyone’s favorite session “Clinical Trials That May Change Your Practice”.

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Google Podcasts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

References:

Oral Amphotericin for Cryptococcal Meningitis: doi 10.1093/cid/ciad440
PALACE: doi 10.1001/jamainternmed.2023.2986
DoxyPEP: doi 10.1056/NEJMoa2211934
RSV Vaccine in Pregnancy: doi 10.1056/NEJMoa2216480
RSV Vaccines in Older Adults: doi 10.1056/NEJMoa2209604 and doi 10.1056/NEJMoa2213836
AURORA: doi 10.1093/cid/ciad709
Mycoses Mapping: doi 10.1093/cid/ciac882

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#89 – IDWeek 2023 Recap: Late Breaking Clinical Trials Dec 22, 2023

Need help narrowing down your IDWeek re-watch content? Or maybe you were unable to make IDWeek so you want the pharmacy driven highlights? Well, look no further, Breakpoints has what you need! Join your Breakpoints hosts, Drs. Erin McCreary (@ErinMcCreary), Julie Ann Justo (@julie_justo), and Jeannette Bouchard (@jlbouchard001) for a review of some of the late breaking clinical trials presented at IDWeek 2023. Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Google Podcasts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ References: 1. Oral Fosfomycin vs IV BL/BLI/Carbapenem in cUTI: doi:10.1093/ofid/ofad500.002 2. Oral Fosfomycin for male UTIs: doi:10.3390/antibiotics11020198 and prostatitis: doi:10.1093/jac/dkz015 3. ATM-AVI for cIAIA or HAP/VAP (REVISIT): doi:10.1093/ofid/ofad500.2476 4. CAZ-AVI for neonates: doi:10.1093/ofid/ofad500.2473 5. ACORN RCT: doi:10.1001/jama.2023.20583

HARMONIE RCT: doi:10.1093/ofid/ofad500.005

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#88 – Dosing Consult: Can we BID farewell to Q8H Metronidazole? Dec 01, 2023

Drs. Nicholas Torney (@NPT_PharmD) and Sunish Shah join Dr. Jeannette Bouchard (@jlbouchard001) to discuss our next topic in our Dosing Consult series: BID vs TID dosing for metronidazole. Deep dive into the PK/PD and real-world application of this switch with experts in this dosing strategy.

References:

Addition of anaerobic coverage in biliary infections: Addition of anaerobic coverage for treatment of biliary tract infections: a propensity score-matched cohort study
Eggerthella lenta and Pipercillin-tazobactam: Eggerthella lenta Bloodstream Infections Are Associated With Increased Mortality Following Empiric Piperacillin-Tazobactam (TZP) Monotherapy: A Population-based Cohort Study
Q12H Dose Schedule in Surgery Prophylaxis: Twelve-hourly dosage schedule for oral and intravenous metronidazole
2018 Clinical Data on Q12H Dosing in Mixed Infections: Clinical efficacy of 12-h metronidazole dosing regimens in patients with anaerobic or mixed anaerobic infections
2021 Clinical Data on Q12H Dosing: Three is a crowd: Clinical outcomes of a twice daily versus a thrice daily metronidazole dosing strategy from a multicenter study

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#87 – We Love T Cells: Updates in Cytomegalovirus Nov 17, 2023

Dr. Ajit Limaye and Dr. Camille Kotton (@KottonNelson) join Dr. Erin McCreary (@ErinMcCreary) to discuss fascinating updates in the CMV space including new RCTs for prevention, vaccines, and more! Learn why a little "hair of the dog" might be a good thing, how great T cells are, and the trials we still need.

References:

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#86 – The Robin to Your Batman: Ensuring Adequate Beta-lactamase Inhibitor Exposure to Restore Beta-lactam Activity Oct 20, 2023

Episode Notes

Drs. Paul Ambrose and Michael Dudley (@MikeMndudley) join Dr. Julie Ann Justo (@julie_justo) for a review of beta-lactamase inhibitor (BLI) pharmacokinetics & pharmacodynamics. They discuss factors affecting BLI’s restorative activity, the convoluted math behind establishing exposure-response relationships for BLIs, some geeky medicinal chemistry, and a little-known easter egg in the published literature.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

References

SIDP Insight on Tazobactam for ESBLs: Monogue M, et al. Pharmacotherapy. 2021 Oct;41(10):864-880. doi: 10.1002/phar.2623. PMID 34689349.
Tazobactam with cefepime: VanScoy BD, et al. Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01052-17. doi: 10.1128/AAC.01052-17. PMID: 28947475.
Another great review of BLIs: Ambrose PG, et al. Curr Opin Pharmacol. 2017 Oct;36:86-93. doi: 10.1016/j.coph.2017.09.001. PMID: 29096172.
Meropenem-vaborbactam target attainment: Bhavnani SM, et al. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0213021. doi: 10.1128/aac.02130-21. PMID: 36374023.
Meropenem-vaborbactam pulmonary exposures: Wenzler E, et al. Antimicrob Agents Chemother. 2015 Dec;59(12):7232-9. doi: 10.1128/AAC.01713-15. PMID: 26349830.
Stand-alone BLI discussion based on CB-618: Ambrose PG, et al.. Antimicrob Agents Chemother. 2017 Nov 22;61(12):e00630-17. doi: 10.1128/AAC.00630-17. PMID: 28947474.
NDM-9 resistance to taniborbactam: Le Terrier C, et al. Lancet Infect Dis. 2023 Apr;23(4):401-402. doi: 10.1016/S1473-3099(23)00069-5. PMID: 36796395.
New boronate drugs and NDM: Lomovskaya O, et al. Antimicrob Agents Chemother. 2023 Aug 31:e0057923. doi: 10.1128/aac.00579-23. PMID: 37650617.
Helpful BLI PK-PD review: Crass R, Pai MP. Pharmacotherapy. 2019 Feb;39(2):182–195. doi: 10.1002/phar.2210. PMID 30589457.
Discovery of QPX7728 (Xeruborbactam): Hecker SJ, et al. J Med Chem. 2020 Jul 23;63(14):7491-7507. doi: 10.1021/acs.jmedchem.9b01976. PMID 32150407.
Xeruborbactam binding to PBPs directly: Lomovskaya O, et al. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0216821. doi: 10.1128/AAC.02168-21. PMID: 34902261.
Xeruborbactam predicted best by fAUC/MIC with oral ceftibuten: Tarazi Z, et al. Open Forum Infect Dis. Volume 9, Issue Supplement_2, December 2022, ofac492.666, https://doi.org/10.1093/ofid/ofac492.666 (Poster 614)
Xeruborbactam predicted best by fAUC/MIC with meropenem: Tarazi Z, et al. Open Forum Infect Dis. Volume 9, Issue Supplement_2, December 2022, ofac492.667, https://doi.org/10.1093/ofid/ofac492.667 (Poster 615)
First 2013 AAC paper on tazobactam with ceftolozane from Ambrose group: VanScoy B, et al. Antimicrob Agents Chemother. 2013 Jun;57(6):2809-14. doi: 10.1128/AAC.02513-12. PMID: 23629705.
Second 2013 AAC paper on tazobactam with ceftolozane from Ambrose group: Vanscoy B, et al. Antimicrob Agents Chemother. 2013 Dec;57(12):5924-30. doi: 10.1128/AAC.00656-13. PMID: 24041895.
Electric Telescope, 52 Class 530 Series 1080p LCD/HD; Samsung Group, Seoul, South Korea, available at: https://www.samsung.com/ca/support/model/LN52C530F1FXZC/
Tazobactam with Piperacillin from Ambrose group: Nicasio AM, et al. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2075-80. doi: 10.1128/AAC.02747-15. PMID: 26787689.

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#85 – Who You Gonna Call? Mythbusters! Antibiotic Myths for Infectious Diseases Clinicians Sep 15, 2023

Episode Notes

Drs. Jason Gallagher (@JGPharmD) and Melissa Johnson (@IDPharmacist) join Dr. Erin McCreary (@ErinMcCreary) to discuss one of the most talked about papers of the year: Antibiotic Myths for the Infectious Diseases Clinician. Tune in to hear these common myths debunked!

Antibiotic Myths for the Infectious Diseases Clinician: https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciad357/7194976?redirectedFrom=fulltext

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#84 – Antimicrobial Stewardship and Disaster Medicine: Perspectives from Ukraine Aug 18, 2023

Episode Notes

In this special episode of Breakpoints, pharmacist Hailie Uren joins Dr. Erin McCreary (@ErinMcCreary) to talk about the current practice of medicine in Ukraine, including the extremely drug-resistant war wound infections she frequently encounters. You won’t want to miss this amazing insight, and can support UK-Med in Ukraine here: https://www.uk-med.org/donate-now

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#83 – Dosing Consult: Sulfamethoxazole/trimethoprim Jul 21, 2023

Episode Notes

In what has been described on Twitter as the “doing your own taxes of medicine,” Drs. Emily Heil (@emilylheil) and Andrew Fratoni (@AFratty) join Dr. Jillian Hayes (@thejillianhayes) to break down the ins and outs of sulfamethoxazole/trimethoprim dosing! Tune in for a discussion on the use of this agent for methicillin-resistant Staphylococcus aureus, gram-negatives, pneumocystis, and Stenotrophomonas maltophilia.

References:

Twitter Thread re: Bactrim dosing: https://twitter.com/IDdocAdi/status/1661174505702674432?s=20
PJP OI Guidelines: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/pneumocystis-0
IDSA Resistant Gram Negative Guidance Document: https://www.idsociety.org/globalassets/idsa/practice-guidelines/amr-guidance/1.0/idsa-amr-guidance-v3.0.pdf
(Lower doses of PJP Treatment): Butler-Laporte G, Smyth E, Amar-Zifkin A, Cheng M, McDonald E, Lee T. Low-dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, Volume 7, Issue 5, May 2020, ofaa112, https://doi-org.proxy-hs.researchport.umd.edu/10.1093/ofid/ofaa112
(DS Vs SS for PJP PPX): Schneider MM, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group. J Infect Dis. 1995;171(6):1632-1636. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7769306.
General Bactrim PK/PD: Trubiano JA, Grayson ML. Trimethoprim and Trimethoprim-Sulfamethoxazole (Cotrimoxazole). Chapter 92, Kucers’ The Use of Antibiotics (7th Edition). Taylor & Francis, 2017.
(2014 IDSA SSTI Guidelines). PMID 24973422
Cadena J, Nair S, Henao-Martinez AF, Jorgensen JH, Patterson JE, Sreeramoju PV. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011 Dec;55(12):5430-2. doi: 10.1128/AAC.00706-11. Epub 2011 Sep 19. PMID: 21930870; PMCID: PMC3232808.
Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect. 2012 Aug;65(2):128-34. doi: 10.1016/j.jinf.2012.03.013. Epub 2012 Mar 21. PMID: 22445732.
Paul M, Bishara J, Yahav D, Goldberg E, Neuberger A, Ghanem-Zoubi N, Dickstein Y, Nseir W, Dan M, Leibovici L. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ. 2015 May 14;350:h2219. doi: 10.1136/bmj.h2219. PMID: 25977146; PMCID: PMC4431679.
Lasko MJ, Gethers ML, Tabor-Rennie JL, Nicolau DP, Kuti JL. In Vitro Time-Kill Studies of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0216721. doi: 10.1128/aac.02167-21. Epub 2022 Jan 10. PMID: 35007135; PMCID: PMC8923228.
Lasko MJ, Tabor-Rennie JL, Nicolau DP, Kuti JL. Trimethoprim/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro chemostat model. J Antimicrob Chemother. 2022 Oct 28;77(11):3187-3193. doi: 10.1093/jac/dkac304. PMID: 36101486.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#82 – ID Literature Year in Review (LIVE from MAD-ID) Jun 23, 2023

Episode Notes

In this special LIVE podcast episode, Drs. Jason Pogue (@jpogue1) and Erin McCreary (@Erin McCreary) present from MAD-ID 2023 (@MAD_ID_ASP) and give a rundown of some of the best ID papers, abstracts, studies, and other cool stuff from late 2022 and early 2023! They cover everything from #ECCMID2023 late breakers to published RCTs to stewardship (but NOT COVID-19!).

Download the slides to view as you listen along here: https://drive.google.com/file/d/130YsgVg9J9di41WVKnB3tBhScYNujUdi/view?usp=sharing

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#81 – Making the Right Choice Easy: Antimicrobial Stewardship in the Emergency Department Jun 16, 2023

Episode Notes

Drs. Zack Nelson (@zacroBID), Alison Dittmer, and Michael Pulia (@DrMichaelPulia) join Dr. Jillian Hayes (@thejillianhayes) to discuss the ins and outs of antimicrobial stewardship in one of the busiest parts of the hospital: the emergency department! Tune in for a discussion on communication considerations in the ED, the role of lipoglycopeptides for common gram-positive syndromes, and a rapid-fire round discussing common stewardship interventions. This podcast was supported by an educational grant from Melinta Therapeutics.

References:

Pulia M, et al. Antimicrobial Stewardship in the Emergency Department. Emerg Med Clin N Am 2018;36(4):853-872. doi: 10.1016/j.emc.2018.06.012. PMID: 30297009.
Rech, Megan A et al. “PHarmacist Avoidance or Reductions in Medical Costs in Patients Presenting the EMergency Department: PHARM-EM Study.” Critical Care Explorations 2021;3(4):e0406. doi:10.1097/CCE.0000000000000406. PMID: 33912836.
Sacdal JPA, Cheon E et al. Oritavancin versus oral antibiotics for treatment of skin and skin structure infections in the emergency department. Am J Emerg Med 2022;60:223-224.
Jenkins TC, Jaukoos JS et al. Patterns of use and perceptions of an institution-specific antibiotic stewardship application among emergency department and urgent care clinicians. Infection Control and Hospital Epidemiology 2020;41:212-215.
Dretske D, Schulz L, Werner E, Sharp B, Pulia M. Effectiveness of oritavancin for management of skin and soft tissue infections in the emergency department: A case series. The American Journal of Emergency Medicine 2021;43:77-80. doi: 10.1016/j.ajem.2021.01.050. PMID: 33545550.
Paul M, Pulia M, Pulcini C. Antibiotic stewardship in the emergency department: not to be overlooked. Clin Microbiol Infect 2021;27(2):172-174. doi: 10.1016/j.cmi.2020.11.015. PMID: 33253938.
Baxa J, McCreary E, Schulz L, Pulia M. Finding the niche: An interprofessional approach to defining oritavancin use criteria in the emergency department. Am J Emerg Med. 2020;38(2):321-324. doi:10.1016/j.ajem.2019.158442.
Pulia MS, Hesse S, Schwei RJ, Schulz LT, Sethi A, Hamedani A. Inappropriate Antibiotic Prescribing for Respiratory Conditions Does Not Improve Press Ganey® Patient Satisfaction Scores in the Emergency Department. Open Forum Infect Dis 2020;7(6): ofaa214. doi:10.1093/ofid/ofaa214.
Pulia MS, Lindenauer PK. Annals for Hospitalists Inpatient Notes - A Critical Look at Procalcitonin Testing in Pneumonia. Ann Intern Med. 2021;174(6):HO2-HO3. doi:10.7326/M21-1913.
Redwood R, Knobloch MJ, Pellegrini DC, Ziegler MJ, Pulia M, Safdar N. Reducing unnecessary culturing: a systems approach to evaluating urine culture ordering and collection practices among nurses in two acute care settings. Antimicrob Resist Infect Control. 2018;7. doi:10.1186/s13756-017-0278-9.
Pulia MS, Schwei RJ, Hesse SP, Werner NE. Characterizing barriers to antibiotic stewardship for skin and soft-tissue infections in the emergency department using a systems engineering framework. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e180. doi:10.1017/ash.2022.316.
May L, Gudger G, Armstrong P, et al. Multisite exploration of clinical decision making for antibiotic use by emergency medicine providers using quantitative and qualitative methods. Infect Control Hosp Epidemiol. 2014;35(9):1114-1125. doi:10.1086/677637.
May L, Cosgrove S, L’archeveque M, et al. A Call to Action for Antimicrobial Stewardship in the Emergency Department: Approaches and Strategies. Ann Emerg Med 2013;62(1):69-77.e2. doi: 10.1016/j.annemergmed.2012.09.002. PMID: 23122955.
Schoffelen T, Schouten JA, Hoogerwerf JJ, et al. Quality indicators for appropriate antimicrobial therapy in the emergency department: a pragmatic Delphi procedure. Clin Microbiol Infect 2021;27(2):210-214. doi: 10.1016/j.cmi.2020.10.027. PMID: 33144204.
Yadav K, Stahmer A, Mistry RD, May L. An Implementation Science Approach to Antibiotic Stewardship in Emergency Departments and Urgent Care Centers. Academic Emergency Medicine 2020; 27(1):31-42. doi: 10.1111/acem.13873. PMID: 31625653.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#80 – Weighting on a Miracle: Understanding Unknowns of Dosing Children and Adults with Obesity Jun 02, 2023

Episode Notes

Drs. Kate Kyler (@kedkyler) and Amit Pai (@DosingMatters) join Dr. Jeannette Bouchard (@jlbouchard001) for a discussion on dosing antibiotics in children and adults affected by obesity! Learn when practitioners should be concerned about drug dosing, what disease states and populations matter most, when we should explore TDM, and more!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#79 – HAP & VAP: Let’s Clear the Air May 26, 2023

Episode Notes

Drs. Dahlia Blake (@dblake096), Owen Albin (@owenralb), and Ryan Rivosecchi join Dr. Erin McCreary (@ErinMcCreary) for a discussion on HAP and VAP! Tune in for a review of the role of dual anti-pseudomonal coverage, optimal anti-MRSA therapy, duration of therapy, and more!

This funding for this episode was provided by Shionogi Inc.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#78 – New Therapies in HIV: The Long Road to Long-acting Antiretrovirals - Are We There Yet? Apr 28, 2023

Episode Notes

Drs. Emily Kirkpatrick, Paul Sax, and Jill Strayer join Dr. Rachel Britt to discuss their experiences using injectable long-acting antiretrovirals, especially cabotegravir/rilpivirine, in their clinics. Listen to learn not only about logistical challenges with these drugs, but also creative solutions to overcome them.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#77 – Breakpoints Talks Breakpoints: Non-fermenters Apr 21, 2023

Episode Notes

Drs. Jim Lewis, Mike Satlin (@MSatlin) and Jason Pogue (@jpogue1) are back with Dr. Erin McCreary (@ErinMcCreary) for the grand finale of our five-episode miniseries all about breakpoints! Join our panelists for a great discourse on breakpoint updates for non-fermenters.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#76 – Breakpoints Talks Breakpoints: Fluoroquinolones Apr 14, 2023

Episode Notes

Drs. Jim Lewis, Mike Satlin (@MSatlin) and Jason Pogue (@jpogue1) are back with Dr. Erin McCreary (@ErinMcCreary) for episode four of a five-episode miniseries all about breakpoints! Join our panelists for a magically delicious episode all about breakpoint updates on fluoroquinolones.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#75 – Breakpoints Talks Breakpoints: Aminoglycosides Apr 07, 2023

Episode Notes

Drs. Jim Lewis, Mike Satlin (@MSatlin) and Jason Pogue (@jpogue1) are back with Dr. Erin McCreary (@ErinMcCreary) for episode three of a five-episode miniseries all about breakpoints! Join our panelists as they discuss breakpoint updates on aminoglycosides.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#74 – Breakpoints Talks Breakpoints: Piperacillin/tazobactam Mar 31, 2023

Episode Notes

Drs. Jim Lewis, Mike Satlin (@MSatlin) and Jason Pogue (@jpogue1) are back with Dr. Erin McCreary (@ErinMcCreary) for episode two of a five-episode miniseries all about breakpoints! Join our panelists as they discuss breakpoint updates on piperacillin/tazobactam.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#73 – You’re a Breakpoint, Harry: Magical Insights from CLSI and USCAST Mar 24, 2023

Episode Notes

Drs. Jim Lewis, Mike Satlin (@MSatlin) and Jason Pogue (@jpogue1) join Dr. Erin McCreary (@ErinMcCreary) for episode one of a five-episode miniseries all about breakpoints!

Over the next five weeks, our panelists will cover breakpoint updates on piperacillin/tazobactam, aminoglycosides, fluoroquinolones, and non-fermenters. You won’t want to miss this series!

Our first episode will tackle questions related to breakpoints themselves – a seemingly mystical art! How does a breakpoint become a breakpoint? How often are breakpoints updated? How do we implement all of these recent breakpoint changes into clinical practice? Tune in for answers to these questions and more!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#72 – This Isn't Just a Phage: A Discussion on Bacteriophage Therapy Mar 17, 2023

Episode Notes

Drs. Saima Aslam (@DocSaimaAslam) and Daria Van Tyne (@DariaVanTyne) join Dr. Rachel Britt (@RachelBPharmD) for a discussion on bacteriophage therapy! Tune in for a review of their role in therapy, logistical considerations, the future of phage therapy, and more!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#71 – This is a Potential Breakup Song: Controversies in the Management of Infective Endocarditis Feb 17, 2023

Episode Notes

Inspired by lamentations on Twitter, Drs. Bobbi Jo Stoner (@BobbiJo_Stoner), Jonathan Ryder (@JonathanRyderMD) and Sami El-Dalati join Dr. Jillian Hayes (@thejillianhayes) to hash out some of the controversies we encounter while managing infective endocarditis. Do we really need gentamicin and rifampin for all cases of staphylococcal prosthetic valve endocarditis? Where do oral antimicrobials fit into this disease state? Who should have a seat at the table to provide the most comprehensive care to these patients? Tune in for the answers to these questions and more!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

References: IDSA/AHA Infective Endocarditis Guidelines: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000296 Deconstructing the Dogma: Systematic Literature Review and Meta-analysis of Adjunctive Gentamicin and Rifampin in Staphylococcal Prosthetic Valve Endocarditis: https://pubmed.ncbi.nlm.nih.gov/36408468/ Twitter Poll – Gabe Vilchez (March 2021): https://twitter.com/IdVilchez/status/1372148761112240131?s=20&t=fYuyNWGmzZACWrpUb7Fp3g Survey of ID Physicians on Gent and Rifampin Use: https://pubmed.ncbi.nlm.nih.gov/32964063/ Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis: https://academic.oup.com/jac/article/52/5/820/760105 Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus: https://journals.asm.org/doi/abs/10.1128/AAC.34.12.2312 Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations: https://journals.asm.org/doi/abs/10.1128/aac.35.12.2611 Rifampin Combination Therapy for Nonmycobacterial Infections: https://journals.asm.org/doi/10.1128/CMR.00034-09 ARREST Trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32456-X/fulltext Is Rifampin Use Associated With Better Outcome in Staphylococcal Prosthetic Valve Endocarditis? A Multicenter Retrospective Study: https://pubmed.ncbi.nlm.nih.gov/32706879/ Nephrotoxicity of vancomycin, alone and with an aminoglycoside: https://pubmed.ncbi.nlm.nih.gov/2351627/ Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia: https://journals.asm.org/doi/10.1128/AAC.02483-18 Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments: https://academic.oup.com/ofid/article/7/1/ofz538/5691187 CERT Trial (in process): https://clinicaltrials.gov/ct2/show/NCT04886284 Rifampin for Surgically Treated Staphylococcal Infective Endocarditis: A Propensity Score-Adjusted Cohort Study: https://pubmed.ncbi.nlm.nih.gov/26872729/ A step-by-step guide to implementing a multidisciplinary endocarditis team: https://journals.sagepub.com/doi/10.1177/20499361211065596 Management of Infective Endocarditis in People Who Inject Drugs: A Scientific Statement from the American Heart Association: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001090?cookieSet=1 Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319263/ A Cross-sectional Analysis of Linezolid in Combination with Methadone or Buprenorphine as a Cause of Serotonin Toxicity: https://academic.oup.com/ofid/article/9/7/ofac331/6625822 POET Trial: https://www.nejm.org/doi/full/10.1056/nejmoa1808312 Risk of New Bloodstream Infections and Mortality Among People Who Inject Drugs With Infective Endocarditis: https://pubmed.ncbi.nlm.nih.gov/32785635/ Comparing right- and left sided injection-drug related infective endocarditis: https://pubmed.ncbi.nlm.nih.gov/33441950/ Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745005/ Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna: https://pubmed.ncbi.nlm.nih.gov/29659732/ Impact of the duration of antibiotic therapy on relapse and survival following surgery for active infective endocarditis: https://academic.oup.com/ejcts/article/55/4/760/5126415 Bacteriological Outcome after Valve Surgery for Active Infective Endocarditis: Implications for Duration of Treatment after Surgery: https://academic.oup.com/cid/article/41/2/187/529954 Long-term Risk of Hemorrhagic Stroke in Patients With Infective Endocarditis: A Danish Nationwide Cohort Study: https://academic.oup.com/cid/article/68/4/668/5039147 Sign of the Times: Updating Infective Endocarditis Diagnostic Criteria to Recognize Enterococcus faecalis as a Typical Endocarditis Bacterium: https://pubmed.ncbi.nlm.nih.gov/35262664/ Prevalence of colorectal disease in Enterococcus faecalis infective endocarditis: results of an observational multicenter study: https://pubmed.ncbi.nlm.nih.gov/31444092/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#70 – Stewardship Struggles Jan 20, 2023

Episode Notes

Drs. Valerie Vaughn (@ValerieVaughnMD), Jason Newland (@JasonGNewland) and Libby Dodds Ashley (@The_Real_LDA) join Dr. Erin McCreary (@ErinMcCreary) for a discussion on how to harness the power of data to move through those common stewie struggles. Tune in for a review of common barriers, the art of communication within stewardship, and more!

This podcast is sponsored by bioMérieux.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

#69 – IDWeek 2022 Recap: Practice Changing Publications – Midnights Edition Dec 30, 2022

Episode Notes

Your Breakpoints hosts, Drs. Erin McCreary (@ErinMcCreary), Julie Ann Justo (@julie_justo), Rachel Britt (@RachelBPharmD) and Jillian Hayes (@thejillianhayes) are back for a second week of IDWeek review. Tune in for publications that may change your practice, and a segment of I Feel Nerdy that is sure to Swiftly become one of your favorites!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials Dec 23, 2022

Episode Notes

Missing IDWeek already? Hoping for some new content to consume during your holiday travel plans? Have no fear – your IDWeek Breakpoints recap is here!

Join your Breakpoints hosts, Drs. Erin McCreary (@ErinMcCreary), Julie Ann Justo (@julie_justo), Rachel Britt (@RachelBPharmD) and Jillian Hayes (@thejillianhayes) for a review of some new trials and pipeline agents presented at IDWeek 2022.

Be sure to stay tuned for Part II, launching next Friday!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#67 – Nixing the Nidus: Managing Retained Sources in Prosthetic Joint Infections Nov 25, 2022

Dr. Laura Certain (@laura_certain) and Dr. Nico Cortes-Penfield (@Cortes_Penfield) join Dr. Julie Ann Justo (@julie_justo) to discuss all things related to prosthetic joint infections. Tune in to learn about what comprises a bacterial biofilm, how it develops, and ways to combat it using the latest evidence-based antibiotic regimens. We also take a look at what’s on the horizon for the field of orthopedic infectious diseases.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References:

Cortés-Penfield NW, Kulkarni PA. The History of Antibiotic Treatment of Osteomyelitis. Open Forum Infect Dis. 2019 Apr 8;6(5):ofz181. doi: 10.1093/ofid/ofz181. PMID: 31123692.
Bernard L, et al. Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection. N Engl J Med. 2021 May 27;384(21):1991-2001. doi: 10.1056/NEJMoa2020198. PMID: 34042388. (DATIPO trial)
Gallagher C, et al. Impact of Implementing an IV to PO Antibiotic Treatment Protocol for Orthopedic Infections ion Prescribing Habits and Health Utilization Outcomes. IDWeek 2022. Poster 909.
Febrile Podcast. Episode #31 – Truth or DAIR. 2022 Feb 28. https://febrilepodcast.com/episode-31-truth-or-dair/
Frank JM, et al. The Mark Coventry, MD, Award: Oral Antibiotics Reduce Reinfection After Two-Stage Exchange: A Multicenter, Randomized Controlled Trial. Clin Orthop Relat Res. 2017 Jan;475(1):56-61. doi: 10.1007/s11999-016-4890-4. PMID: 27387759.
Kelly MP, et al. Extended Oral Antibiotics Increase Bacterial Resistance in Patients Who Fail 2-Stage Exchange for Periprosthetic Joint Infection. J Arthroplasty. 2022 Aug;37(8S):S989-S996. doi: 10.1016/j.arth.2022.01.027. PMID: 35074446.
Payne J, et al. Inducing Antimicrobial Resistance with Long-term Antibiotics at Stage 2 Revision for Periprosthetic Joint Infection. IDWeek 2022. Poster 981.
Frost P, et al. Phototoxic potential of minocycline and doxycycline. Arch Dermatol. 1972 May;105(5):681-3. PMID: 5026677.
Lode H, et al. Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother. 1979 Jul;16(1):1-6. doi: 10.1128/AAC.16.1.1. PMID: 475366.
Sader HS, et al. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers. Diagn Microbiol Infect Dis. 1993 Aug-Sep;17(2):143-50. doi: 10.1016/0732-8893(93)90025-3. PMID: 8243035.
Green S & Tsai YV. Precision Dosing of To-Marrow: Linezolid Therapeutic Drug Monitoring. ContagionLive: Bench to Bedside with SIDP. 2022 Nov 3. https://www.contagionlive.com/view/precision-dosing-of-to-marrow-linezolid-therapeutic-drug-monitoring

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#66 – The Swinging PEN-dulum: Evolving Approaches to Cephalosporin Use in Penicillin Allergic Patients Nov 18, 2022

Dr. Kimberly Blumenthal (@KimberlyBlumen1), Dr. Meghan Jeffres (@PharmerMeg), and Dr. Eric Macy (@EricMacyMD) join Dr. Julie Ann Justo (@julie_justo) to summarize the history of cephalosporin avoidance in penicillin allergies, evidence-based pros and cons of giving cephalosporins in penicillin allergy, how to leverage technology to improve treatment of patients with penicillin allergies, and much more!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

Macy E. Why Was There Ever a Warning Not to Use Cephalosporins in the Setting of a Penicillin "Allergy"? J Allergy Clin Immunol Pract. 2021 Nov;9(11):3929-3933. doi: 10.1016/j.jaip.2021.06.059. PMID: 34303019.
Liang EH, et al. Adverse Reactions Associated with Penicillins, Carbapenems, Monobactams, and Clindamycin: A Retrospective Population-based Study. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1302-1313.e2. doi: 10.1016/j.jaip.2019.11.035. PMID: 31821919.
Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: A retrospective population-based analysis. J Allergy Clin Immunol. 2015 Mar;135(3):745-52.e5. doi: 10.1016/j.jaci.2014.07.062. PMID: 25262461.
Macy E, et al. Population-Based Incidence of New Ampicillin, Cephalexin, Cefaclor, and Sulfonamide Antibiotic "Allergies" in Exposed Individuals with and without Preexisting Ampicillin, Cephalexin, or Cefaclor "Allergies". J Allergy Clin Immunol Pract. 2022 Feb;10(2):550-555. doi: 10.1016/j.jaip.2021.10.043. PMID: 34757066.
Picard M, et al. Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses. J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2722-2738.e5. doi: 10.1016/j.jaip.2019.05.038. PMID: 31170539.
Romano A, et al. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. J Allergy Clin Immunol. 2016 Jul;138(1):179-186. doi: 10.1016/j.jaci.2016.01.025. PMID: 27016799.
Romano A, et al. Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins. J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1662-1672. doi: 10.1016/j.jaip.2018.01.020. PMID: 29408440.
Blumenthal KG, et al. The Impact of a Reported Penicillin Allergy on Surgical Site Infection Risk. Clin Infect Dis. 2018 Jan 18;66(3):329-336. doi: 10.1093/cid/cix794. PMID: 29361015.
Blumenthal KG, et al. Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ. 2018 Jun 27;361:k2400. doi: 10.1136/bmj.k2400. PMID: 29950489.
Blumenthal KG, et al. Recorded Penicillin Allergy and Risk of Mortality: a Population-Based Matched Cohort Study. J Gen Intern Med. 2019 Sep;34(9):1685-1687. doi: 10.1007/s11606-019-04991-y. PMID: 31011962.
Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: A cohort study. J Allergy Clin Immunol. 2014 Mar;133(3):790-6. doi: 10.1016/j.jaci.2013.09.021. PMID: 24188976.
AAAI. Choosing Wisely. 2014 Mar 3. https://www.choosingwisely.org/clinician-lists/american-academy-allergy-asthma-immunlogy-non-beta-lactam-antibiotics-penicillin-allergy/
Jeffres MN, et al. Systematic review of professional liability when prescribing β-lactams for patients with a known penicillin allergy. Ann Allergy Asthma Immunol. 2018 Nov;121(5):530-536. doi: 10.1016/j.anai.2018.03.010. PMID: 29551402.
Macy E, et al. Association Between Removal of a Warning Against Cephalosporin Use in Patients With Penicillin Allergy and Antibiotic Prescribing. JAMA Netw Open. 2021 Apr 1;4(4):e218367. doi: 10.1001/jamanetworkopen.2021.8367. PMID: 33914051.
Blumenthal KG, et al. Addressing Inpatient Beta-Lactam Allergies: A Multihospital Implementation. J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):616-625.e7. doi: 10.1016/j.jaip.2017.02.019. PMID: 28483315.
Jeffres M. Penicillin and/or Beta-Lactam Allergy Tip Sheet & Cross-reactivity Table. https://drive.google.com/file/d/1cokYXnSDlO3vk8ke1LaalPz4iavuNSV8/view?usp=share_link
Khan DA, et al. Drug allergy: A 2022 practice parameter update. J Allergy Clin Immunol. 2022 Sep 17:S0091-6749(22)01186-1. doi: 10.1016/j.jaci.2022.08.028. Epub ahead of print. PMID: 36122788.
Guyer AC, et al. Allergy Electronic Health Record Documentation: A 2022 Work Group Report of the AAAAI Adverse Reactions to Drugs, Biologicals, and Latex Committee. J Allergy Clin Immunol Pract. 2022 Nov;10(11):2854-2867. doi: 10.1016/j.jaip.2022.08.020. PMID: 36151034.
Iammatteo M, et al. Safety and Outcomes of Oral Graded Challenges to Amoxicillin without Prior Skin Testing. J Allergy Clin Immunol Pract. 2019 Jan;7(1):236-243. doi: 10.1016/j.jaip.2018.05.008. PMID: 29802906.
Bavbek S, et al. Determinants of nocebo effect during oral drug provocation tests. Allergol Immunopathol (Madr). 2015 Jul-Aug;43(4):339-45. doi: 10.1016/j.aller.2014.04.008. PMID: 25088674.
DePestel DD, et al. Cephalosporin use in treatment of patients with penicillin allergies. J Am Pharm Assoc (2003). 2008 Jul-Aug;48(4):530-40. doi: 10.1331/JAPhA.2008.07006. PMID: 18653431.

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#65 – Into the Unknown: Exploring Fever of Unknown Origin with Febrile Podcast Oct 14, 2022

In this special collaborative episode, Dr. Sara Dong (@swinndong) of Febrile podcast (@febrilepodcast) and Dr. Ghady Haidar (@cleverwebber) join Dr. Erin McCreary (@ErinMcCreary) to discuss all aspects of FUO, including classification, diagnosis, management, and more! Have the fever of unknown origin review article from the February 2022 edition of NEJM (@NEJM) handy to follow along with the group.

References Haidar G, Singh N. Fever of unknown origin. N Engl J Med 2022;386:463-77.

LinkedIn: https://www.linkedin.com/company/sidp/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#64 – Putting the Fun in Fungi: A Fun-guide to New Antifungals Sep 23, 2022

In this spore-tacular episode of Breakpoints, Drs. Nathan Wiederhold and Kayla Stover (@stoverkr) join Dr. Erin McCreary (@ErinMcCreary) to discuss updates on the antifungal pipeline, offer pearls regarding their place in therapy, and teach us how to pronounce the drug names.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

Hoenigl M, Sprute R, Egger M, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81(15):1703-29.

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#63 – I Never Metapneumovirus that Required Antibiotics: Prevention & Treatment of Common Respiratory Viruses in Adults Sep 16, 2022

Episode Notes

Drs. Ann Falsey, Crystal Hodge (@Howzzeee) and Michael Ison (@MichaelGIsonMD) join Dr. Jillian Hayes (@thejillianhayes) for a review of non-COVID respiratory viruses. Tune in for a review of current epidemiological changes, the vaccine pipeline, and current treatment options.

This episode was supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp

References

Community-acquired respiratory viruses in transplant patients (PMID 31511250)
Clinical Transplantation 2019 special issue on Transplant Infectious Diseases Guidelines: ](https://urldefense.com/v3/https:/onlinelibrary.wiley.com/toc/13990012/2019/33/9;!!OToaGQ!ujpO69U-82gjgidcyi6YshodQ4umKoYBRbC6wcHf-7QtOVoXotlCzZSwBl7eXjGal8O6D5qQIF8k7_GUOsi3weedNyWNXbw$)[https://onlinelibrary.wiley.com/toc/13990012/2019/33/9
ECIL-4 Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus https://doi.org/10.1093/cid/cis844
JID RSV Supplements: https://academic.oup.com/jid/issue/226/Supplement_1, https://academic.oup.com/jid/issue/226/Supplement_2
CID Precision Vaccinology Supplement: https://academic.oup.com/cid/issue/75/Supplement_1
Net State of Immunosuppression (PMID 32803228)
Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies (PMID 30520987)
Biologic response modifiers (PMID 28263774)
Invasive fungal infections and targeted therapies in hematologic malignancies (PMID 34947040)
Impact of COVID-19 on Influenza vaccination strategies (PMID 35607766)
Zanamivir vs oseltamivir (PMID 35299245)
Peramivir vs oseltamivir (PMIDs 33447633, 33006445)
FLAGSTONE (PMID 35085510)
CAPSTONE-2 (PMID 32526195)
Neuraminidase inhibitor benefits beyond 48 hours (PMID 33434667, 32898685, 24815805, 24268590)
Baloxavir for prophylaxis of household contacts (PMID 32640124)
Oral ribavirin for RSV in HCT (PMID 30202920)
Ribavirin for RSV and human metapneumovirus in HCT (PMID 32162389)
DAS181 for parainfluenza virus (PMID 33569576)

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#62 – Novel TheraPOOtics: The Microbiome, C. difficile, and LBPs Aug 26, 2022

In this spore-tacular episode of Breakpoints, Drs. Anne Gonzales-Luna (@anniejayTX) and Paul Feuerstadt (@DrPaulGastro) join Dr. Rachel Britt (@rachelbpharmd) to discuss the microbiome, its relationship to C. difficile, and the new area of microbiota-based live biotherapeutic products (LBPs).

This podcast was sponsored by an unrestricted medical education grant from Ferring Pharmaceuticals.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#61 – Dosing Consult: Linezolid Therapeutic Drug Monitoring Aug 19, 2022

In the second episode of Breakpoints' Dosing Consult series, Drs. Ryan Crass (@crasspofungin) and Amit Pai (@DosingMatters) join Dr. Jillian Hayes (@thejillianhayes) to break down the 5 Ws and 1 H of linezolid TDM.

LinkedIn: https://www.linkedin.com/company/sidp/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx

Bibliography

Abdul-Aziz MH, et al. Intensive Care Med. 2020 Jun;46(6):1127-1153. doi: 10.1007/s00134-020-06050-1. Epub 2020 May 7. PMID: 32383061.
Abdul-Aziz MH, et al. Ther Drug Monit. 2022 Feb 1;44(1):19-31. doi: 10.1097/FTD.0000000000000940. PMID: 34750338.
Andes D, et al. Antimicrob Agents Chemother. 2002;46(11):3484-3489. doi:10.1128/AAC.46.11.3484-3489.2002. PMID: 12384354.
Bandín-Vilar E, et al. Clin Pharmacokinet. 2022;61(6):789-817. doi:10.1007/s40262-022-01125-2. PMID: 35699914.
Boak LM, Rayner CR, Grayson ML, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother. 2014;58(4):2334-2343. doi:10.1128/AAC.01885-13. PMID: 24514086.
Crass RL, et al. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00605-19. doi: 10.1128/AAC.00605-19. PMID: 31109977.
Cojutti P, et al. Clin Pharmacokinet. 2018 Aug;57(8):989-1000. doi: 10.1007/s40262-017-0606-5. PMID: 29080937.
Dong HY, et al. Eur J Clin Microbiol Infect Dis. 2014;33(6):1029-1035. doi:10.1007/s10096-013-2041-3. PMID: 24515096.
Matsumoto K, et al. Int J Antimicrob Agents. 2014;44(3):242-247. doi:10.1016/j.ijantimicag.2014.05.010. PMID: 25108880.
Meagher AK, et al. Antimicrob Agents Chemother. 2003;47(2):548-553. doi:10.1128/AAC.47.2.548-553.2003. PMID: 12543657.
Obach RS. Drug Metab Dispos. 2022 Apr;50(4):413-421. doi: 10.1124/dmd.121.000776. PMID: 35042700.
Pea F, et al. Antimicrob Agents Chemother. 2010 Nov;54(11):4605-10. doi: 10.1128/AAC.00177-10. Epub 2010 Aug 23. PMID: 20733043.
Pea F, et al. J Antimicrob Chemother. 2012 Aug;67(8):2034-42. doi: 10.1093/jac/dks153. Epub 2012 May 2. PMID: 22553142.
Rao GG, et al. Ther Drug Monit. 2020 Feb;42(1):83-92. doi: 10.1097/FTD.0000000000000710. PMID: 31652190.
Rayner CR, et al. Clin Pharmacokinet. 2003;42(15):1411-23. doi: 10.2165/00003088-200342150-00007. PMID: 14674791.
Taubert M, et al. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5254-61. doi: 10.1128/AAC.00356-16. PMID: 27324768.
Society of Infectious Diseases Pharmacists | Contagion Live

Laboratories that offer linezolid assay results:

Infectious Disease Pharmacokinetics Laboratory (https://idpl.pharmacy.ufl.edu/ )
Atlantic Diagnostics Laboratories (https://atlanticdiagnosticlaboratories.com/lab-tests )
National Jewish Health PK Laboratory (ttps://www.nationaljewish.org/for-professionals/diagnostic-testing/adx/tests/linezolid,-level)

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#60 – Going MAD for Non-COVID ID Literature: A Year in Review LIVE from MAD-ID Jul 22, 2022

In this special LIVE podcast episode, Drs. Emily Heil (@emilylheil) and Erin McCreary (@Erin McCreary) sit down at MAD-ID 2022 (@MAD_ID_ASP) and give a rundown of 36 of some of the best ID papers, abstracts, studies, and other cool stuff from 2021 and early 2022! They cover everything from ECCMID late breakers to gram-negative RCTs to stewardship to fungi (but NOT COVID-19). Listen now!

Handout: https://drive.google.com/file/d/1OdYP9WpNGFmslw_G_vTPYF0cJZoxN8jo/view

LinkedIn: https://www.linkedin.com/company/sidp/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx

References PMIDs

IMPRESU: 34620666
TARGET: 35106617
MERINO-2: 34395716
Tazobactam SIDP Insight: 34689349
TMP-SMX vs FQ for Steno: 35097154
Elexacaftor-Tezacaftor-Ivacaftor: 35142340
Antibiotic Inertia: 34596206
Antibiotic Overuse at Discharge: 34554249
Pharmacist-Driven TOC: 35536577
Tele-stewardship: 34141816
MRSA Surveillance Culture: 29340593
MRSA Screen Durability: 33788910
Antifungal Pipeline: 34626339
Antifungal Susceptibility Testing: 347784889
Posa vs Vori for Aspergillosis: 33549194
AMBITION: 35320642
FLAGSTONE: 35085510
SOLSTICE: 34864943
Probiotics for Primary Prevention: 33972996
Probiotics and VAP: 34546300
SER-109: 35045228
Bayesian vs First-Order Vanc AUC: 35134264
Beta-lactam Admin Order: 34606585
Candida Endophthalmitis: 34293405
FUO Review: 35108471
7 vs 14 Days for Male UTI: 34313686

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#59 – Resistance in Pseudomonas aeruginosa: Pearls and Perils Jul 15, 2022

Drs. Antonio Oliver (@aoliverp73) and Maggie Monogue (@MaggieMonogue) join Dr. Erin McCreary (@Erin McCreary) to discuss all things Pseudomonas aeruginosa. Tune in to learn from some of the best about the complexities of P. aeruginosa resistance, the role of various antibiotics in the management of DTR isolates, and much more!

This podcast was sponsored by an unrestricted medical education grant from Abbvie.

LinkedIn: https://www.linkedin.com/company/sidp/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx

References Shields RK, et al. Clin Infect Dis. 2022;ciac097. doi: 10.1093/cid/ciac097.

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#58 – We're Gonorrhea-valuate: Updates and Implementation of STI Treatment Guidelines Jun 24, 2022

Drs. Brian Werth (@bdubrx), Zack Nelson (@zacroBID) and Amy Brotherton (@AmyBrother10) join Dr. Jillian Hayes (@thejillianhayes) to discuss updates in the management of sexually transmitted infections. Listen in for guidance on how doses are selected, practical implementation of guideline changes, and how to discuss these changes with patients.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

St. Cyr S, et al. Update to CDC’s Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1911–1916. doi: http://dx.doi.org/10.15585/mmwr.mm6950a6.
STI treatment guidelines. Centers for Disease Control and Prevention. https://www.cdc.gov/std/treatment-guidelines/default.htm. Published 2021. Accessed May 12, 2022.
National overview – sexually transmitted Disease SURVEILLANCE, 2019. Centers for Disease Control and Prevention. https://www.cdc.gov/std/statistics/2019/overview.htm. Published April 13, 2021. Accessed May 12, 2022.
Doan T, et al. N Engl J Med. 2020 Nov 12;383(20):1941-1950. doi: 10.1056/NEJMoa2002606. PMID: 33176084.
Doan T, et al. N Engl J Med. 2019 Jun 6;380(23):2271-2273. doi: 10.1056/NEJMc1901535. PMID: 33167060.
Kong FYS, et al. Clin Infect Dis. 2014 Jul 15;59(2):193-205. doi: 10.1093/cid/ciu220. PMID: 24729507.
Dombrowski JC, et al. Clin Infect Dis. 2021 Sep 7;73(5):842-831. doi: 10.1093/cid/ciab153. PMID: 33606009.
Connolly KL, et al. Antimicrob Agents Chemother. 2019 Feb 26;63(3):e01644-18. doi: 10.1128/AAC.01644-18. PMID: 30642924.
Páez-Canro C, et al. Cochrane Database Syst Rev. 2019 Jan 25;1(1):CD010871. doi: 10.1002/14651858.CD010871.pub2. PMID: 30682211.
Dukeres-Muijrers NHTM, et al. Sex Transm Infect. 2021 Mar;97(2):147-151. doi: 10.1136/sextrans-2020-054558. Epub 2020 Jul 31. PMID: 32737209.
Manavi K, et al. Int J STD AIDS. 2016 Dec;27(14):1303-1308. doi: 10.1177/0956462415614723. Epub 2015 Oct 27. PMID: 26511655.
Chisholm SA, et al. J Antimicrob Chemother. 2010 Oct;65(10):2141-8. doi: 10.1093/jac/dkq289. Epub 2010 Aug 6. PMID: 20693173.
Kastner U, et al. Infection. 2001 Oct;29(5):251-6. doi: 10.1007/s15010-001-1072-3. PMID: 11688901.
Dellamonica P. J Antimicrob Chemother. 2002 Oct;50(4):614-5. doi: 10.1093/jac/dkf166. PMID: 12356813.
Davidson RJ. Infect Drug Resist. 2019 Mar 8;12:585-596. doi: 10.2147/IDR.S187226. PMID: 30881064.
Burr LD, et al. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0224621. doi: 10.1128/aac.02246-21. PMID: 35293783.
Hepatitis C State of Medicaid Access: https://stateofhepc.org

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#57 – Dosing Consult: Ceftriaxone May 27, 2022

Drs. Tom Dilworth and Stephanie Shealy May (@stephshealymay) join Dr. Rachel Britt (@RachelBPharmD) in the first episode of Breakpoints Dosing Consults to discuss questions and debates around ceftriaxone dosing. When should we use 1g over 2g? How does critical illness affect what dose to use? Is ceftriaxone the most approachable antibiotic? Tune in for answers to these questions and more!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

Ettestad PJ, Campbell GL, Welbel SF, Genese CA, Spitalny KC, Marchetti CM, Dennis DT. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis. 1995 Feb;171(2):356-61. doi: 10.1093/infdis/171.2.356. PMID: 7844372.
Hasegawa S, Sada R, Yaegashi M, Morimoto K, Mori T; Adult Pneumonia Study Group-Japan. 1g versus 2 g daily intravenous ceftriaxone in the treatment of community onset pneumonia - a propensity score analysis of data from a Japanese multicenter registry. BMC Infect Dis. 2019 Dec 26;19(1):1079. doi: 10.1186/s12879-019-4552-8. PMID: 31878894; PMCID: PMC6933656.
Barber KE, Loper JT, Morrison AR, Stover KR, Wagner JL. Impact of Obesity on Ceftriaxone Efficacy. Diseases. 2020 Jul 9;8(3):27. doi: 10.3390/diseases8030027. PMID: 32660113; PMCID: PMC7563366.
Herrera-Hidalgo L, de Alarcón A, López-Cortes LE, Luque-Márquez R, López-Cortes LF, Gutiérrez-Valencia A, Gil-Navarro MV. Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs? Antimicrob Agents Chemother. 2020 Dec 16;65(1):e02099-20. doi: 10.1128/AAC.02099-20. Erratum in: Antimicrob Agents Chemother. 2021 May 18;65(6): PMID: 33046488; PMCID: PMC7927845.
Herrera-Hidalgo L, Lomas-Cabezas JM, López-Cortés LE, Luque-Márquez R, López-Cortés LF, Martínez-Marcos FJ, de la Torre-Lima J, Plata-Ciézar A, Hidalgo-Tenorio C, García-López MV, Vinuesa D, Gutiérrez-Valencia A, Gil-Navarro MV, De Alarcón A. Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT. J Clin Med. 2021 Dec 21;11(1):7. doi: 10.3390/jcm11010007. PMID: 35011748; PMCID: PMC8745305.
Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. doi: 10.15585/mmwr.rr7004a1. PMID: 34292926; PMCID: PMC8344968.
Whittles LK, White PJ, Paul J, Didelot X. Epidemiological Trends of Antibiotic Resistant Gonorrhoea in the United Kingdom. Antibiotics (Basel). 2018 Jul 13;7(3):60. doi: 10.3390/antibiotics7030060. PMID: 30011825; PMCID: PMC6165062.
Ackerman A, Zook NR, Siegrist JF, Brummitt CF, Cook MM, Dilworth TJ. Comparison of Clinical Outcomes among Intensive Care Unit Patients Receiving One or Two Grams of Ceftriaxone Daily. Antimicrob Agents Chemother. 2020 May 21;64(6):e00066-20. doi: 10.1128/AAC.00066-20. PMID: 32205348; PMCID: PMC7269488.
Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011 Feb;50(2):99-110. doi: 10.2165/11539220-000000000-00000. PMID: 21142293.
Dailly E, Arnould JF, Fraissinet F, Naux E, Letard de la Bouralière MA, Bouquié R, Deslandes G, Jolliet P, Le Floch R. Pharmacokinetics of ertapenem in burns patients. Int J Antimicrob Agents. 2013 Jul;42(1):48-52. doi: 10.1016/j.ijantimicag.2013.02.021. Epub 2013 Apr 8. PMID: 23578794.
Pai MP. Treatment of bacterial infections in obese adult patients: how to appropriately manage antimicrobial dosage. Curr Opin Pharmacol. 2015 Oct;24:12-7. doi: 10.1016/j.coph.2015.06.004. Epub 2015 Jun 25. PMID: 26119488.
Mahmood I. Theoretical versus empirical allometry: Facts behind theories and application to pharmacokinetics. J Pharm Sci. 2010 Jul;99(7):2927-33. doi: 10.1002/jps.22073. PMID: 20127826.
Kang N, Housman ST, Nicolau DP. Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for Commonly Utilized Parenteral Agents against Methicillin-Susceptible Staphylococcus aureus: Focus on Ceftriaxone Discordance between Predictive Susceptibility and in Vivo Exposures. Pathogens. 2015 Jul 30;4(3):599-605. doi: 10.3390/pathogens4030599. PMID: 26264030; PMCID: PMC4584275.
Gern BH, Greninger AL, Weissman SJ, Stapp JR, Tao Y, Qin X. Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus. Ann Clin Microbiol Antimicrob. 2018 Feb 20;17(1):5. doi: 10.1186/s12941-018-0257-x. PMID: 29463249; PMCID: PMC5819674.
Bremmer DN, Balada-Llasat JM, Goff DA, Bauer KA. Ceftriaxone Etest non-susceptible methicillin susceptible Staphylococcus aureus time-kill responses. Diagn Microbiol Infect Dis. 2017 Jun;88(2):192-194. doi: 10.1016/j.diagmicrobio.2017.02.019. Epub 2017 Mar 2. PMID: 28291629.
Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010 May;54(5):1670-7. doi: 10.1128/AAC.00019-10. Epub 2010 Mar 1. PMID: 20194704; PMCID: PMC2863635.
Palmer SM, Kang SL, Cappelletty DM, Rybak MJ. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob Agents Chemother. 1995 Aug;39(8):1764-71. doi: 10.1128/AAC.39.8.1764. PMID: 7486916; PMCID: PMC162823.
Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):89-96. doi: 10.1016/0732-8893(95)00053-d. PMID: 7587056.
Garot D, Respaud R, Lanotte P, Simon N, Mercier E, Ehrmann S, Perrotin D, Dequin PF, Le Guellec C. Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol. 2011 Nov;72(5):758-67. doi: 10.1111/j.1365-2125.2011.04005.x. PMID: 21545483; PMCID: PMC3243010.
Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother. 2001 Apr;47(4):421-9. doi: 10.1093/jac/47.4.421. PMID: 11266414.
Van Wart SA et al., ICAAC 2009, poster # A1-010
Housman ST, Sutherland CA, Nicolau DP. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents. 2014 Sep;44(3):235-41. doi: 10.1016/j.ijantimicag.2014.05.012. Epub 2014 Jun 24. PMID: 25052866.
Zelenitsky SA, Beahm NP, Iacovides H, Ariano RE, Zhanel G. Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis. J Antimicrob Chemother. 2018 Jul 1;73(7):1888-1894. doi: 10.1093/jac/dky120. PMID: 29635472.
Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, Leibovici L, Bishara J. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect. 2011 Oct;17(10):1581-6. doi: 10.1111/j.1469-0691.2010.03425.x. Epub 2010 Dec 14. PMID: 21073629.
Carr DR, Stiefel U, Bonomo RA, Burant CJ, Sims SV. A Comparison of Cefazolin Versus Ceftriaxone for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia in a Tertiary Care VA Medical Center. Open Forum Infect Dis. 2018 May 18;5(5):ofy089. doi: 10.1093/ofid/ofy089. PMID: 30568987; PMCID: PMC5961173.

Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.

#56 – Empiric Escalation: Gazing into the Crystal Ball for Multidrug-Resistant Gram-Negatives Apr 15, 2022

Drs. Kate DeSear (@IDPharmD_Kate) and Frank Tverdek (@FTverdek) join Dr. Julie Ann Justo (@julie_justo) to discuss the practice of empiric escalation in this episode of our gram-negative resistance series. Listen in for encouragement on following your intuition and tips on how, when, and why to practice this other side of antimicrobial stewardship.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

Clinical and Laboratory Standards Institute. Access Our Free Resources: M100 and M60. Accessed at https://clsi.org/standards/products/free-resources/access-our-free-resources/
Gallagher JC, et al. Open Forum Infect Dis. 2018 Oct 31;5(11):ofy280. doi: 10.1093/ofid/ofy280. PMID: 30488041.
Castan B, et al. Infect Dis Now. 2021 Sep;51(6):532-539. doi: 10.1016/j.idnow.2021.05.003. Epub 2021 May 17. PMID: 34015539.
Cultrera R, et al. Antibiotics (Basel). 2020 Sep 24;9(10):640. doi: 10.3390/antibiotics9100640. PMID: 32987821.
Strich JR, et al. Clin Infect Dis. 2021 Feb 16;72(4):611-621. doi: 10.1093/cid/ciaa061. PMID: 32107536.
Montravers P, Bassetti M. Curr Opin Infect Dis. 2018 Dec;31(6):587-593. doi: 10.1097/QCO.0000000000000490. PMID: 30299359.
Strich JR, Heil EL, Masur H. J Infect Dis. 2020 Jul 21;222(Suppl 2):S119-S131. doi: 10.1093/infdis/jiaa221. PMID: 32691833.
Kumar A, et al. Crit Care Med. 2006 Jun;34(6):1589-96. doi: 10.1097/01.CCM.0000217961.75225.E9. PMID: 16625125.
Hibbard ML, et al. Surg Infect (Larchmt). 2010 Oct;11(5):427-32. doi: 10.1089/sur.2009.046. PMID: 20818984.
Rosa RG, Goldani LZ, dos Santos RP. BMC Infect Dis. 2014 May 23;14:286. doi: 10.1186/1471-2334-14-286. PMID: 24884397.
Benanti GE, et al. Antimicrob Agents Chemother. 2019 Jan 29;63(2):e01813-18. doi: 10.1128/AAC.01813-18. PMID: 30509935.

#55 – One World: Global Perspectives in Antimicrobial Stewardship Mar 25, 2022

Drs. Debbie Goff (@idpharmd), Khalid Eljaaly (@khalideljaaly), and Angeliki Messina (@AngPharmID) join Dr. David Ha (@DHpharmd) as part of a global panel discussion on international antimicrobial stewardship practices. Listen in to learn about pharmacy practice in South Africa and Saudi Arabia, antimicrobial stewardship practices in these and other countries, and how you too can get involved in global stewardship.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

2022 ACCP Global Conference on Clinical Pharmacy. https://www.accp.com/meetings/abstracts.aspx
Alhazzani W, Alshahrani M, Alshamsi F, Aljuhani O, Eljaaly K, Hashim S, et al. The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section. J Infect Public Health. 2022;15(1):142-151. doi:10.1016/j.jiph.2021.10.005.
Brink AJ, Messina AP, Feldman C, et al. Antimicrobial stewardship across 47 South African hospitals: an implementation study. Lancet Infect Dis. 2016;16(9):1017-1025. doi:10.1016/S1473-3099(16)30012-3
Goff DA, Ashiru‐Oredope D, Cairns KA, et al. Global contributions of pharmacists during the COVID‐19 pandemic. J Am Coll Clin Pharm. Published online October 2, 2020:10.1002/jac5.1329. doi:10.1002/jac5.1329
Eljaaly K, Elarabi S, Alshehri S, Nix DE. Impact of requiring re-authorization of restricted antibiotics on day three of therapy. J Antimicrob Chemother 2018;73(2):527-530. doi:10.1093/jac/dkx384.
Korayem GB, Badreldin HA, Eljaaly K, et al. Clinical pharmacy definition, required education, training and practice in Saudi Arabia: A position statement by the Saudi society of clinical pharmacy. Saudi Pharm J. 2021;29(11):1343-1347. doi:10.1016/j.jsps.2021.09.008.
International Pharmaceutical Federation Development Goals: Antimicrobial Stewardship. https://developmentgoals.fip.org/dg17/
Messina AP, van den Bergh D, Goff DA. Antimicrobial Stewardship with Pharmacist Intervention Improves Timeliness of Antimicrobials Across Thirty-three Hospitals in South Africa. Infect Dis Ther. 2015;4(Suppl 1):5-14. doi:10.1007/s40121-015-0082-x
Open Access BSAC eBook "Antimicrobial Stewardship: From Principles to Practice". https://www.bsac.org.uk/antimicrobialstewardshipebook/BSAC-AntimicrobialStewardship-FromPrinciplestoPractice-eBook.pdf
Open Access BSAC course "Antimicrobial Stewardship for the Gulf, Middle East and North Africa". https://www.futurelearn.com/courses/antimicrobial-stewardship-for-the-middle-east
Saudi Society of Clinical Pharmacy Infectious Disease Pharmacy Specialty Network. https://sscp.org.sa/infectious-disease/
World Health Organization. Antimicrobial Stewardship Programmes in Health-Care Facilities in Low- and Middle-Income Countries: A WHO Practical Toolkit. World Health Organization; 2019. Accessed March 9, 2022. http://apps.who.int/iris/handle/10665/329404

#54 – Connecting with our Colleagues: COVID-19 Treatments in Community Pharmacies Mar 18, 2022

Dr. Jennifer Morrow joins Dr. Rachel Britt (@RachelBPharmD) on this bonus episode of the Breakpoints podcast to discuss how the introduction of COVID-19 therapeutics and vaccines has affected community pharmacy teams and workflows. Also mentioned are the recent Test to Treat initiative, impacts on future community pharmacy practice, and ways inpatient providers can help our community colleagues.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References:

https://aspr.hhs.gov/TestToTreat/Documents/Fact-Sheet.pdf
Torres, N. S., Abercrombie, J. J., Srinivasan, A., Lopez-Ribot, J. L., Ramasubramanian, A. K., & Leung, K. P. (2016). Screening a commercial library of pharmacologically active small molecules against staphylococcus aureus biofilms. Antimicrobial Agents and Chemotherapy, doi:10.1128/AAC.00377-16
ASPR. (2022). COVID-19 therapeutics locator. Retrieved from https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/
Dunn, A. (2021). Texas appeals court: Judge had no authority to order ivermectin for patient suffering from COVID-19 aftereffects. Retrieved from https://www.law.com/texaslawyer/2021/11/22/texas-appeals-court-judge-had-no-authority-to-order-ivermectin-for-patient-suffering-from-covid-aftereffects/
Services, Howard Fischer Capitol Media. (). Pharmacists would have to fill ivermectin prescriptions for COVID under arizona proposal. Arizona Daily Star Retrieved from https://tucson.com/news/local/pharmacists-would-have-to-fill-ivermectin-prescriptions-for-covid-under-arizona-proposal/article_eca12e7c-5781-11ec-a775-cb73d778d4fb.html
Sexton, A. (2022, -01-19). Bill would make it easier to obtain ivermectin in new hampshire. Wmur Retrieved from https://www.wmur.com/article/ivermectin-new-hampshire-state-house-bill/38817240
Saunders, J. (2022). No ‘legal right’ to force use of ivermectin, court says. Retrieved from https://www.clickorlando.com/news/local/2022/01/29/no-legal-right-to-force-use-of-ivermectin-court-says/
Tidd, J. (2022, -01-27). Kansas bill would force pharmacists to fill ivermectin, hydroxychloroquine as off-label COVID treatment. The Topeka Capital-Journal Retrieved from https://www.cjonline.com/story/news/coronavirus/2022/01/25/kansas-politicians-off-label-ivermectin-hydroxychloroquine-covid-treatment-pharmacists/9198489002/

#53 – Abscessus and fortuitum and avium, Oh My!: Updates and Controversies in NTM Management Feb 18, 2022

Drs. Wendi Drummond and Jeff Pearson (@jeffpears0n) join Dr. Rachel Britt (@RachelBPharmD) on the Breakpoints podcast this week to discuss all things on non-tuberculosis mycobacteria pulmonary infections. Listen for answers to all your burning questions like “Are we still using IV amikacin?” and “How do I get omadacycline for my patient?” as well as learning why clofazimine is the coolest drug out there. For more NTM content, check out Dr. Drummond’s podcast, NTMTalk!

This podcast was sponsored by an unrestricted medical education grant from Paratek.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References:

#52 – A Conversation with the Authors of IDSA Guidance on Treatment of AmpC, CRAB, and Stenotrophomonas Jan 28, 2022

Drs. Pranita Tamma (@pranita_tamma) and Sam Aitken (@OncIDPharmd) are BACK on the podcast this week with Dr. Erin McCreary (@ErinMcCreary) to discuss IDSA guidance on AmpC producers, carbapenem-resistant Acinetobacter baumanii, and Stenotrophomonas as part of our series on gram-negative bacteria. Listen as the panelists navigate the hot mess that is the CRAB treatment landscape, have a minocycline appreciation moment (we stan for Steno Sam!), and throw down some bar trivia in an "I Feel Nerdy" segment that you don't want to miss.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References

#51 – A Conversation with the Authors of IDSA Guidance on Treatment of ESBL, CRE, and DTR Pseudomonas Jan 21, 2022

Drs. Pranita Tamma (@pranita_tamma) and Sam Aitken (@OncIDPharmd), authors of the IDSA Guidance on gram-negative resistance, join Dr. Erin McCreary (@ErinMcCreary) for this exquisitely good episode to discuss the soon-to-be-updated guidance on treatment of ESBL producers, CRE producers, and difficult to treat (DTR) Pseudomonas.

Learn more about the Society of Infectious Diseases Pharmacists:

Website: https://sidp.org/About
Twitter: @SIDPharm (https://twitter.com/SIDPharm)
Instagram: @SIDPharm (https://www.instagram.com/sidpharm/)
Facebook: https://www.facebook.com/sidprx
LinkedIn: https://www.linkedin.com/company/sidp/

References:

#50 – Moving to the Algo-rhythm of IDWeek 2021: Highlights in SoMe and ASP Dec 17, 2021

Episode Notes

Drs. Timothy Gauthier (@IDstewardship) and Jillian Hayes (@thejillianhayes) join Dr. Zahra Kassamali Escobar (@zkePharmD) to recap some IDWeek 2021 highlights on social media and antimicrobial stewardship.

The views and opinions expressed in this podcast are that of the speakers and do not necessarily reflect those of any past, current, or potential future employer.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References:

Vosoughi S et al. The spread of true and false news online. Science 2018;359:1146-1151. doi: 10.1126/science.aap9559.
Solis Arce JS et al. COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries. Nature Medicine 2021;27:1385-1394. doi: 10.1038/s41591-021-01454-y.
Metlay JP et al. Tensions in antibiotic prescribing: pitting social concerns against the interests of individual patients. J Gen Intern Med 2002;17(2):87-94. doi: 10.1046/j.1525-1497.2002.10711.x.
Wang et al. Development of Multifaceted Antimicrobial Stewardship Curriculum for Undergraduate Medical Education: The Antibiotic Stewardship, Safety, utilization, Resistance, and Evaluation (ASSURE) Elective. _Open Forum Infect Dis _2021;8(6): ofab231. https://doi.org/10.1093/ofid/ofab231.
Charani E et al. Understanding the Determinants of Antimicrobial Prescribing Within Hospitals: The Role of “Prescribing Etiquette.” Clin Infect Dis 2013;57(2):188-196. doi: 10.1093/cid/cit212.
Lines TH et al. Driving antimicrobial use improvement: attitudes of providers of adult hospital care on optimal attribution and feedback. Infect Control Hosp Epidemiol 2018;39(8):983-985. doi: 10.1017/ice.2018.113.
Teshome BF et al. Duration of Exposure to Antipseudomonal B-Lactam Antibiotics in the Critically Ill and Development of New Resistance. Pharmacotherapy 2019;39(3):261-270. doi: 10.1002/phar.2201.
Teshome BF et al. Evaluation of a ceiling effect on the association of new resistance development to antipseudomonal beta-lactam exposure in the critically ill. Infect Control Hosp Epidemiol 2020;41(4):484-485.
Leone M et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014;40: 1399-1408. doi: 10.1007/s00134-014-3411-8.
Stevens V et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011;53(1):42-48. doi: 10.1093/cid/cir301.
Bhalodi A et al. Impact of antimicrobial therapy on the gut microbiome. J Antimicrob Chemother 2019;74(Suppl 1):i6-i15. doi: 10.1093/jac/dky530.

#49 – A PGY-What Now? A Primer on ID Pharmacy Fellowships Dec 03, 2021

Episode Notes

Drs. Keith Rodvold and Taylor Morrisette (@TayMorrisette) join Dr. Julie Ann Justo (@julie_justo) to discuss ID pharmacy fellowships, their pros and cons compared to other post-graduate training opportunities, the ID "pharmily tree," and Mai Tais.

Find more information on ID pharmacy fellowships available in the United States here: -SIDP Fellowship Listings -ACCP Directory of Residencies, Fellowships, and Graduate Training Programs

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#48 – Aligning Goals: Antibiotics in End of Life Care Nov 19, 2021

Drs. Molly Sinert and Jon Furuno join Dr. David Ha (@DHpharmd) to discuss the prevalence of antibiotic use and its harms and benefits in reducing suffering and providing comfort during end-of-life care.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References:

Sinert et al. Guidance for Safe and Appropriate Use of Antibiotics in Hospice Using a Collaborative Decision Support Tool. Accessed October 6, 2021. https://oce-ovid-com.laneproxy.stanford.edu/article/00129191-202008000-00005/HTMLA
Albrecht JS, McGregor JC, Fromme EK, Bearden DT, Furuno JP. A Nationwide Analysis of Antibiotic Use in Hospice Care in the Final Week of Life. Journal of Pain and Symptom Management. 2013;46(4):483-490. doi:10.1016/j.jpainsymman.2012.09.010
Furuno JP, Noble BN, Fromme EK. Should we refrain from antibiotic use in hospice patients? Expert Review of Anti-infective Therapy. 2016;14(3):277-280. doi:10.1586/14787210.2016.1128823
Servid SA, Noble BN, Fromme EK, Furuno JP. Clinical Intentions of Antibiotics Prescribed Upon Discharge to Hospice Care. Journal of the American Geriatrics Society. 2018;66(3):565-569. doi:10.1111/jgs.15246
Gaw CE, Hamilton KW, Gerber JS, Szymczak JE. Physician Perceptions Regarding Antimicrobial Use in End-of-Life Care. Infection Control & Hospital Epidemiology. 2018;39(4):383-390. doi:10.1017/ice.2018.6
Broom J, Broom A, Good P, Lwin Z. Why is optimisation of antimicrobial use difficult at the end of life? Internal Medicine Journal. 2019;49(2):269-271. doi:10.1111/imj.14200
Kwon KT. Implementation of Antimicrobial Stewardship Programs in End-of-Life Care. Infect Chemother. 2019;51(2):89-97. doi:10.3947/ic.2019.51.2.89
Datta R, Topal J, McManus D, et al. Perspectives on antimicrobial use at the end of life among antibiotic stewardship programs: A survey of the Society for Healthcare Epidemiology of America Research Network. Infection Control & Hospital Epidemiology. 2019;40(9):1074-1076. doi:10.1017/ice.2019.194
Lopez S, Vyas P, Malhotra P, et al. A Retrospective Study Analyzing the Lack of Symptom Benefit With Antimicrobials at the End of Life. Am J Hosp Palliat Care. 2021;38(4):391-395. doi:10.1177/1049909120951748
Ito H. Antibiotics in end-of-life care: What is the driving factor? Infectious Diseases Now. Published online July 7, 2021. doi:10.1016/j.idnow.2021.07.003
Kates OS, Krantz EM, Lee J, et al. Association of Physician Orders for Life-Sustaining Treatment With Inpatient Antimicrobial Use at End of Life in Patients With Cancer. Open Forum Infectious Diseases. 2021;8(8). doi:10.1093/ofid/ofab361
Hickman SE, Nelson CA, Moss AH, Tolle SW, Perrin NA, Hammes BJ. The consistency between treatments provided to nursing facility residents and orders on the physician orders for life-sustaining treatment form. J Am Geriatr Soc. 2011; 59(11): 2091–2099. doi:10.1111/j.1532-5415.2011.03656.x.
Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clinical Infectious Diseases, Volume 62, Issue 10, 15 May 2016, Pages e51–e77, https://doi.org/10.1093/cid/ciw118

#47 – A Nefarious Orchestra: Gram-Negative Resistance Mechanisms Part 2 Oct 29, 2021

From generating 150 liters-worth of E. coli to the first X-ray crystallography of an ESBL, Drs. Robert Bonomo, Ryan Shields (@ryankshields), and Erin McCreary (@ErinMcCreary) take a deep dive into beta-lactamases like AmpCs, KPCs, and more.

#46 – A Nefarious Orchestra: Gram-Negative Resistance Mechanisms Part 1 Oct 22, 2021

Mechanisms of antibiotic resistance help us understand and recognize antibiotic susceptibility patterns that don't make sense. Robert Bonomo and Ryan Shields (@ryankshields) join Erin McCreary (@ErinMcCreary) to discuss efflux and porin mechanisms of resistance in Gram negative bacteria and their impact on antibacterial treatment.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#45 – Expectation vs. Reality: An Insider look at the OVERCOME and MERINO-2 trials Sep 24, 2021

Pathogen-directed trials are among the most important trials that clinicians need to guide therapy but are also incredibly difficult to design and enroll. Rachel Britt (@RachelBPharmD) gets a behind-the-scenes interview with Adam Stewart (@adm_stewart), lead investigator of MERINO-2, and Jason Pogue (@jpogue1), lead investigator of OVERCOME. They discuss original intentions and evolving expectations to investigate optimal antibiotic therapy for multidrug resistant bacteria. Listen in for the insider analysis!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#44 – The VaxScene, a review of the COVID-19 vaccine landscape in the US with a focus on equitable distribution and vaccine hesitancy Sep 17, 2021

Jacinda Abdul-Mutakabbir (@jayCdoesID) and Jeannette Bouchard (@jlbouchard001) join Erin McCreary (@ErinMcCreary) to discuss COVID vaccines, including access to, confidence in, and hesitancy around them. This episode was sponsored by an unrestricted educational grant from Janssen Therapeutics, Division of Janssen Products, LP

References:

Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383:2603-2615.
Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384:403-416.
Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021
Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1094-1099. DOI: http://dx.doi.org/10.15585/mmwr.mm7032e4external icon.
Rapaka RR, Hammershaimb EA, Neuzil KM. Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines [published online ahead of print, 2021 Mar 6]. Clin Infect Dis. 2021;ciab213. doi:10.1093/cid/ciab213
ACIP Website: https://www.cdc.gov/vaccines/acip/index.html
Marcelin JR, Swartz TH, Bernice F, et al. Addressing and Inspiring Vaccine Confidence in Black, Indigenous, and People of Color (BIPOC) during the COVID-19 Pandemic. [published online ahead of print, 2021 Aug 9]. Open Forum Infect Dis. 2021. Doi: 10.1093/ofid/ofab417
Abdul-Mutakabbir JC, Casey S, Jews V, et al. A three-tiered approach to address barriers to COVID-19 vaccine delivery in the Black community. Lancet Glob Health. 2021 Jun;9(6):e749-e750. doi: 10.1016/S2214-109X(21)00099-1. Epub 2021 Mar 10.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#43 – Level Up: Implementation of Beta-lactam Therapeutic Drug Monitoring Aug 27, 2021

Erin McCreary (@erinmccreary) reviews clinical data and implementation strategies for therapeutic drug monitoring of beta-lactam antibiotics with Veena Venugopalan (@Veena_PharmD), Joseph Kuti, Jason Roberts (@jasonroberts_pk), and Marc Scheetz (@IDPharmacometrx).

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#42 – The Level is in the Details: Beta-lactam Therapeutic Drug Monitoring Aug 20, 2021

Erin McCreary (@erinmccreary) discusses clinical rationale behind therapeutic drug monitoring of beta-lactam antibiotics with Veena Venugopalan (@Veena_PharmD), Joseph Kuti, Jason Roberts (@jasonroberts_pk), and Marc Scheetz (IDPharmacometrx).

For BCIDP credit, visit https://sidp.org/BCIDP

References:

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#41 – The Gray Zone: Antimicrobial Stewardship in Immunocompromised Hosts Jul 16, 2021

Promoting evidence-based antimicrobial stewardship for patients with immunocompromising conditions can be tricky when they’re often excluded from clinical studies. Dr. Zahra Kassamali Escobar (@ZKEPharmD) explores this gray zone with Dr. Catherine Liu and Dr. Justine Ross (@abella_ross)

References:

Fluoroquinolone Prophylaxis

Bucaneve et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353:977-87. DOI: 10.1056/NEJMoa044097
Cullen et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353:988-98. DOI: 10.1056/NEJMoa050078
Drayson et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicenter, double-blind, placebo-controlled, randomized, phase 3 trial. Lancet Oncology 2019; 20(12):1760-72. DOI: 10.1016/S1470-2045(19)30506-6
Satlin et al. Colonization with fluoroquinolone-resistant enterobacterales decreases the effectiveness of fluoroquinolone prophylaxis in hematopoietic cell transplant recipients. Clin Infect Dis 2021 May 6. doi: 10.1093/cid/ciab404.

Antibiotic Treatment and Microbiome Implications

Aguilar-Guisado M, et al. Optimisation of empirical antimicrobial therapy in patients with haemotological malignancies and febrile neutropenia (How Long study): an open-label, randomized, controlled, phase 4 trial. Lancet Haematol. 2017 Dec;4(12):e573-83. doi: 10.1016/S2352-3026(17)30211-9.
Shono et al. Gut microbiome injury in allogeneic haematopoietic stem cell transplantation. Nat Rev Cancer. 2018;18(5):283-95. doi: 10.1038/nrc.2018.10.
Weber et al. Microbiome disruption induced by early use of broad-spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(5):845-52. doi: 10.1016/j.bbmt.2017.02.006
Pinato et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5(12):1774-78. doi:10.1001/jamaoncol.2019.2785

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#40 – Breakpoints Talks Breakpoints: Microbiology Labs and Stewardship Jun 18, 2021

In this episode, host Dr. Erin McCreary (@erinmccreary) talks all things micro labs and stewardship with Dr. Romney Humphries (@romneyinla), Dr. Mary Hutton (@m3rkat), and Dr. Joseph Lutgring. From cascading results and breakpoint changes, to making connections within and outside of the lab, we hope you listen, laugh, and learn!

> Show notes:

Mary’s paper: Microbiology Comment Nudge Improves Pneumonia Prescribing - PubMed (nih.gov)
CDC Key Activities and Roles for Microbiology Lab Staff in Antibiotic Stewardship Programs: Key Activities and Roles for Microbiology Laboratory Staff in Antibiotic Stewardship Programs Updated: August 2020 (cdc.gov)
CDC Selective Reporting: Selective Reporting of Antimicrobial Susceptibility Testing Results: A Primer for Antibiotic Stewardship Programs (cdc.gov)
CLSI M100
EUCAST Breakpoints: EUCAST: Clinical breakpoints and dosing of antibiotics
USCAST Breakpoints: Breakpoints - USCAST

#39 – A Little More on the Littles: What Adults Should Know about ID Pediatrics May 21, 2021

In this rapidfire episode Dr. Erin Weslander (@littlebugdrug), Dr. Laura Bio (@StanfordPedsASP), and Dr. Diana Yu (@dyupharmd) reveal their super-secret ID toolkit to figure out dosing and approaches to treatment in pediatric patients.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#38 – You're KID-ding! Myths in ID Pediatrics Apr 23, 2021

Dr. Erin Weslander (@littlebugdrug), Dr. Laura Bio (@StanfordPedsASP), and Dr. Diana Yu (@dyupharmd) breakdown common myths about antimicrobials in pediatric patients.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#37 – A Gab about Cab: The Short on Long-Acting Antiretrovirals for HIV Apr 16, 2021

Dr. Fidelia Bernice, Dr. Rodrigo Burgos, and Dr. Neha Pandit, join Breakpoints to discuss the first available long-acting antiretroviral agent, cabotegravir/rilpivirine.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#36 – Monoclonal Antibodies: Gateway Drugs for Future Care Delivery Models Mar 26, 2021

Dr. Susan Davis (@IDPharmProf), Dr. Emily Spivak (@EmilySpivak), and Dr. Minkey Wungwattana (@minkeyw) join Dr. Erin McCreary (@ErinMcCreary) to discuss individual and shared experiences operationalizing COVID-19 monoclonal antibody therapy across their institutions and states. They tackle big and small hurdles from finding ways to ensure equitable distribution to pronouncing the drug names!

This episode was sponsored by an unrestricted grant from Regeneron Pharmaceuticals.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#35 – Oral Beta-Lactams, Are We Serious? Mar 19, 2021

Dr. Jill Cowper (@jillcowper), and Dr. Jesse Sutton, join host Dr. Zahra Kassamali Escobar (@zkePharmD) to discuss the data behind use of oral beta-lactams as step-down therapy for bacteremia and other serious infections.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

References:

Sutton J, Stevens V, Chang NN et al. Oral β-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source. JAMA Netw Open. 2020 Oct 1;3(10):e2020166.
Punjabi C, Tien V, Meng C, et al. Oral Fluoroquinolone or Trimethoprim-Sulfamethoxazole vs ß-Lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis, Open Forum Infect Dis 2019; 6(10):ofz364.
Tamma PD, Conley AT, Cosgrove SE, et al. Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia. JAMA Intern Med 2019; 179(3):316-323.
Mercuro NJ, Stogsdill P, Wungwattana M. Retrospective analysis comparing oral stepdown therapy for enterobacteriaceae bloodstream infections: fluoroquinolones versus beta-lactams. Int J Antimicrob Agents 2018;51(5)687-692.
Kutob LF, Justo JA, Bookstaver BA et al. Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections. Int J Antimicrob Agents 2016 Nov;48(5):498-503.
Mogle BT, Beccari MV, Steele JM, et al. Clinical considerations for oral beta-lactams as step-down therapy for Enterobacteriaceae bloodstream infections. Expert Opin Pharmacother. 2019 Jun;20(8):903-907.
Migils C, Rhodes NJ, Kuti JL, et al. Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window. Int J Antimicrob Agents 2017;50(3):487-490.
Sandberg T, Englund G, Lincoln K, Nilsson LG. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis. 1990;9(5):317-323.
Mahoney MV, Swords KE. Fluoroquinolones: Friends or Foe? Clin Infect Dis. Clin Infect Dis. 2021 Feb 19:ciab150.
Arensman K, Shields M, Beganovic M, et al. Fluoroquinolone versus beta-lactam oral step-down therapy for uncomplicated streptococcal bloodstream infections. Antimicrob Agents Chemother 2020;64(11):e01515-20.
Seaton RA, Ritchie ND, Robb F, et al. From 'OPAT' to 'COpAT': implications of the OVIVA study for ambulatory management of bone and joint infection. J Antimicrob Chemother. 2019 Aug 1;74(8):2119-2121.

#34 – The New Scoop on Poop: Updates in the Management of C. difficile infections Feb 19, 2021

Dr. Kevin Garey (@GareyKgarey), Dr. Kelly Reveles (@KellyReveles), Dr. Mandelin Cooper, and host Dr. Rachel Britt (@RachelBPharmD) discuss proposed updates of the IDSA-SHEA C. difficile guidelines, including: fidaxomicin over oral vancomycin as first-line therapy, the roles and logistical hurdles of fecal microbiota transplant, bezlotoxumab, and the pros and cons of prophylaxis.

Timestamps

1:16 - Panel introductions 3:19 - Fidaxomicin vs PO vancomycin for first occurrence 7:21 - Fidaxomicin cost effectiveness 11:26 - Factors to consider for health systems when considering switch to fidaxomicin 14:23 - Fidaxomicin vs PO vancomycin for recurrences 17:52 - Role of pulsed and tapered PO vancomycin 19:57 - Role of fecal microbiota transplant (FMT) 22:24 - Challenges of FMT and where pharmacy fits in 27:27 - Bezlotoxumab 31:54 - Feasibility issues with bezlotoxumab and strategies to address them 35:25 - CDI prophylaxis 40:28 - Stewardship's role in reducing C. difficile infections

References

Fidaxomicin Cost-effectiveness

Reveles KR, et al. Pharmacotherapy. 2017;37(12):1489-97.
Watt M, et al. Infection. 2016;44(5):599-606.
Cornely OA, et al. J Antimicrob Chemother. 2018;73(9):2529-39.
Rubio-Terres C, et al. Eur J Clin Microbiol Infect Dis. 2019;38(6):1105-11.

Bezlotoxumab

Wilcox MH, et al. N Engl J Med. 2017;376:305-17.
Oksi J, et al. Eur J Clin Microbiol Infect Dis. 2019;38(10):1947-52.
Hengel RL, et al. Open Forum Infect Dis. 2020;7(4):ofaa097.

Bezlotoxumab Cost-effectiveness

Salavert M, et al. Adv Ther. 2018;35(11):1920-34.
Prabhu VS, et al. Clin Infect Dis. 2018;66(3):355-62.

Primary prophylaxis

Pereiras MA, et al. Biol Blood Marrow Transplant. 2017; 23:S395.
Ganetsky A, et al. Clin Infect Dis. 2019;68(12):2003-2009.
Mullane KM, et al. Clin Infect Dis. 2019; 68(2):196–203.

Secondary prophylaxis

Carignan A, et al. Am J Gastroenterol. 2016;111:1834-1840.
Van Hise NW, et al. Clin Infect Dis. 2016;63:651-653.
Splinter et al. Ann Pharmacother. 2018;52:113-119.
Knight EM, et al. J Pharm Pract. 2019;:897190019825994.
Morrisette T, et al. Biol Blood Marrow Transplant. 2019;25(10):2091-2097.

#33 – A Lung Time Coming: Controversies in Community Acquired Pneumonia Jan 15, 2021

Join Dr. Elizabeth Covington (@ewood_1875), Dr. Brandon Dionne (@BWDionne), Dr. Jason Pogue (@jpogue1), and Dr. David Ha (@DHpharmd) as they discuss new and old antibiotic therapies for community acquired pneumonia, just how typical are atypicals, what happened to HCAP, and much more! This episode was sponsored by an unrestricted educational grant from Paratek Pharmaceuticals

Time stamps: 00:00 Intro, guest bios 03:54 Procalcitonin 10:06 Pneumococcal and legionella antigen testing 16:30 Outpatient CAP therapy 23:40 Newer agents 31:18 Inpatient CAP therapy 39:09 Atypical coverage for admitted patients 44:27 Beta-lactam combination therapy 46:58 Ceftaroline vs ceftriaxone for pneumococcal pneumonia 55:23 Steroid use in CAP

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#32 – Unsolicited Advice: An Honest Discussion of Burnout in Stewardship Dec 18, 2020

Join Dr. Julie Szymczak @julieszymczak, Dr. Emily Heil @emilylheil, Dr. Zahra Kassamali Escobar @zkepharmd, and Dr. Erin McCreary @erinmccreary, for a discussion on stewardship burnout—what is it, who is at risk for it, and what can we do about it?

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#31 – “Mind the Gap”: Antimicrobial Stewardship at Transitions of Care Nov 20, 2020

Antimicrobial stewardship is often an inpatient effort and overlooked at transitions of care. Dr. April Dyer (@aprildyerid) and Dr. Rachel Kenney (@rkenneypharmd) share insight with host Dr. David Ha (@DHpharmD) on current practice and barriers, and strategies for pharmacists to bring antimicrobial stewardship in the discharge process.

Episode content:

00:14: Welcome and introductions:
04:39: Project overview: "Developing Patient Safety Outcome Measures and Measurement Tools for Antimicrobial Stewardship Program”
06:45: Scope of the problem (Scarpato et al.)
07:56: Michigan data (Vaughn et al.)
09:13: Building a business case
12:32: Where to Start?
12:54: Henry Ford Health System experience
15:18: IT solutions
17:22: 1% rule
20:26: Identifying and engaging key players
20:47: Outpatient pharmacy
22:29: Skilled nursing facilities
23:19: Case management relationship
24:23: Barriers to implementation
29:08: Quantifying total duration
30:00: Identify electronic methods to capture total duration therapy attributable to hospitalization
32:16: CDC recommendation "Use the shortest effective antibiotic duration"
33:16: Final remarks & acknowledgements
34:38: Outro

References:

Scarpato SJ, Timko DR, Cluzet VC, et al. An Evaluation of Antibiotic Prescribing Practices Upon Hospital Discharge. Infection Control and Hospital Epidemiology. 2017;38(3):353-355. doi:10.1017/ice.2016.276
Madaras-Kelly KJ, Burk M, Caplinger C, et al. Total duration of antimicrobial therapy in veterans hospitalized with uncomplicated pneumonia: Results of a national medication utilization evaluation. Journal of Hospital Medicine. 2016;11(12):832-839. doi:10.1002/jhm.2648
Feller J, Lund BC, Perencevich EN, et al. Post-discharge oral antimicrobial use among hospitalized patients across an integrated national healthcare network. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020;26(3):327-332. doi:10.1016/j.cmi.2019.09.016
Daniels LM, Weber DJ. Interventions to improve antibiotic prescribing at hospital discharge: A systematic review. Infection Control and Hospital Epidemiology. Published online September 1, 2020:1-4. doi:10.1017/ice.2020.367
Vaughn VM, Gandhi TN, Chopra V, et al. Antibiotic Overuse after Hospital Discharge: A Multi-Hospital Cohort Study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. Published online September 11, 2020. doi:10.1093/cid/ciaa1372
Dyer AP, Dodds Ashley E, Anderson DJ, et al. Total duration of antimicrobial therapy resulting from inpatient hospitalization. Infection Control and Hospital Epidemiology. 2019;40(8):847-854. doi:10.1017/ice.2019.118
Bianchini ML, Kenney RM, Lentz R, Zervos M, Malhotra M, Davis SL. Discharge Delays and Costs Associated with Outpatient Parenteral Antimicrobial Therapy for High priced Antibiotics. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. Published online October 31, 2019. doi:10.1093/cid/ciz1076

Disclosures Dr. April Dyer and Rachel Kenney report no relevant financial disclosures. SIDP reports no relevant financial disclosures.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#30 – Is More Better? The Role of Combination Therapy for MRSA Oct 09, 2020

Host Erin McCreary (@erinmccreary) and expert panelists Dr. Katie Barber (@IDKatieBarb), Dr. Warren Rose (@Warren_E_Rose), and Dr. Steven Tong (@syctong) discuss data from early laboratory work to randomized, clinical trials for various antibiotic combinations used in the treatment of MRSA bacteremia. This was our most requested topic to cover on Breakpoints, and we hope you enjoy!

Please complete this brief survey to help us continue to improve Breakpoints content: https://docs.google.com/forms/d/e/1FAIpQLSeriW-TAgiBik2_gdJllCZ4WqADhUyFIZtTAgYAYxRU5YU3hA/viewform?vc=0&c=0&w=1&flr=0

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#29 – What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 2 Sep 11, 2020

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) discuss notable infectious diseases publications from the first half of 2020.

Papers discussed:

1) Van Duin D, et al. Lancet Infect Dis. 2020 Jun;20(6):731-741. doi: 10.1016/S1473-3099(19)30755-8. 2) Livermore DM, et al. Clin Infect Dis. 2020 Feb 6;ciaa122. doi: 10.1093/cid/ciaa122. 3) Falcone M, et al. Clin Infect Dis. 2020 May 19;ciaa586. doi: 10.1093/cid/ciaa586. 4) Lodise TP, et al. J Antimicrob Chemother. 2020 May 28;dkaa197. doi: 10.1093/jac/dkaa197. 5) O’Donnell JN, et al. Clin Ther. 2020 Jul 16;S0149-2918(20)30315-5. doi: 10.1016/j.clinthera.2020.06.005. 6) Abdul-Aziz MH, et al. Intensive Care Med. 2020 Jun;46(6):1127-1153. doi: 10.1007/s00134-020-06050-1. 7) Cusumano JA, et al. Am J Health Syst Pharm. 2020 Jul 7;77(14):1104-1112. doi: 10.1093/ajhp/zxaa128. 8) Roberts JA, et al. Clin Infect Dis. 2020 Mar 9;ciaa224. doi: 10.1093/cid/ciaa224. 9) Ackerman A, et al. Antimicrob Agents Chemother. 2020 May 21;64(6):e00066-20. doi: 10.1128/AAC.00066-20. 10) Tong SYC, et al. JAMA. 2020 Feb 11;323(6):527-537. doi: 10.1001/jama.2020.0103. 11) Jones BE, et al. JAMA Intern Med. 2020 Feb 17;180(4):552-560. doi: 10.1001/jamainternmed.2019.7495. 12) Cheng MP, et al. Clin Infect Dis. 2020 Jul 15;ciaa1000. doi: 10.1093/cid/ciaa1000.

For BCIDP credit, visit https://sidp.org/BCIDP

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#28 – What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 1 Sep 04, 2020

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) discuss notable infectious diseases publications from the first half of 2020!

Papers discussed:

1) Rybak MJ, et al. Am J Health Syst Pharm. 2020 May 19;77(11):835-864. doi: 10.1093/ajhp/zxaa036. 2) Scheetz MH. Am J Health Syst Pharm. 2020 May 19;77(11):810-811. doi: 10.1093/ajhp/zxaa076. 3) Alosaimy S, et al. Clin Infect Dis. 2020 July 27;ciaa1039. doi: 10.1093/cid/ciaa1039. 4) Rhee C, et al. Clin Infect Dis. 2020 May 6;ciaa059. doi: 10.1093/cid/ciaa059. 5) Heil EL, et al. Pharmacotherapy. 2020 Apr;40(4):368-371. doi: 10.1002/phar.2384. 6) Townsend SR, et al. Clin Infect Dis. 2020 May 6;ciaa458. doi: 10.1093/cid/ciaa458. 7) Satlin MJ, et al. Clin Infect Dis. 2020 Feb 13;ciaa121. doi: 10.1093/cid/ciaa121. 8) Pogue JM, et al. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e01495-19. doi: 10.1128/AAC.01495-19. 9) Ambrose PG, et al. Open Forum Infect Dis. 2020 Mar 13;7(7):ofaa084. doi: 10.1093/ofid/ofaa084. 10) Singh N, et al. JAMA. 2020 Apr 14;323(14):1378-1387. doi: 10.1001/jama.2020.3138. 11) van Delden C, et al. Clin Infect Dis. 2020 Jan 9;ciz1113. doi: 10.1093/cid/ciz1113. 12) Niederman MS, et al. Lancet Infect Dis. 2020 Mar;20(3):330-340. doi: 10.1016/S1473-3099(19)30574-2. 13) von Dach E, et al. JAMA. 2020 Jun 2;323(21):2160-2169. doi: 10.1001/jama.2020.6348. 14) Mergenhagen KA, et al. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02167-19. doi: 10.1128/AAC.02167-19.

For BCIDP credit, visit https://sidp.org/BCIDP

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#27 – Expert Updates in Gram Negative Resistance: Q&A Session Jul 31, 2020

This is part 2 of a continuing education series produced in partnership with the SIDP Education Center (SIDPEC) on gram-negative bacterial resistance. It features expert speakers, Drs. Keith Kaye (@Keith_S_Kaye) and Kimberly Claeys (@ClaeysKcclaeys) and host Julie Ann Justo (@julie_justo). If you missed part 1 of this series, delivered as a webinar lecture, please go to sidp.org/SIDPEC to view that portion of the series first. In this podcast, our experts answer a collation of > 150 questions from interested viewers on the nuances of gram-negative bacterial resistance, from real-world formulary considerations to microbiology lab implementation and more.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#26 – OPAT - The Final Frontier, Part 2 Jun 19, 2020

Gain insight into Outpatient Parenteral Antibiotic Therapy (OPAT) practices across the country from Drs. Jessie Ortwine (@jkortwine), Monica Mahoney (@mmpharmd), Keenan Ryan (@keenanconazole), Monica Donnelley (@DonnelleyMonica), and Meera Mehta.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#25 – Remdesivir: Ethical and Practical Considerations for Allocation, Tracking, and More Jun 18, 2020

Drs. Julie Ann Justo (@julie_justo), Erin McCreary (@erinmccreary), and Helen Newland (@helennewland) discuss ethical allocation of Emergency Use Authorization remdesivir for patients with COVID-19.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#24 – OPAT – The Final Frontier, Part 1 Jun 12, 2020

Gain insight into Outpatient Parenteral Antibiotic Therapy (OPAT) practices across the country from Drs. Jessie Ortwine (@jkortwine), Monica Mahoney (@mmpharmd), Keenan Ryan (@keenanconazole), Monica Donnelley (@DonnelleyMonica), and Meera Mehta.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#23 – Taking a “BITE” Out of Antibiotic Prescribing: Strategies to Improve Antimicrobial Usage in Dentistry May 22, 2020

Dr. Katie Suda (@sudamonas) and Dr. Erinne Kennedy join Dr. Zahra Escobar (@zkepharmd) of the Breakpoints team to discuss strategies to improve antibiotic utilization and forge connections with our dental colleagues to achieve a common goal of improved patient outcomes.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#22 – Taking a “BITE” Out of Antibiotic Prescribing: The Need for Antimicrobial Stewardship in Dentistry May 15, 2020

Dr. Katie Suda (@sudamonas) and Dr. Erinne Kennedy join Dr. Zahra Escobar (@zkepharmd) of the Breakpoints team to discuss why dentists prescribe 1 in 10 of all antibiotics in the United States and how COVID-19 risks are being managed among dentists and other oral health providers.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#21 – Frontline Allies: Emergency Medicine and Critical Care Insights into COVID19 Apr 27, 2020

Dr. Jenny Koehl (@jlkoehl), Dr. Karen Berger (@karenccrx), and Dr. Karen Dohr join host Erin McCreary (@erinmccreary) to discuss taking care of patients with COVID-19 in the Emergency Department and Intensive Care Unit. Listen as the team reflects on their first patients, PPE, anticoagulation, corticosteroid controversies, and more!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#20 – What is Happening Right Now? COVID-19 Challenges and Silver Linings Apr 13, 2020

Julie Ann Justo (@julie_justo), Jason Pogue (@jpogue1), and Erin McCreary (@erinmccreary) discuss critically evaluating COVID-19 literature, staying calm in the storm, strategies for team education and communication, and the role of social media in a pandemic.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#19 – Push and Pull: Combating Antibiotic Resistance from Discovery to Market Reform Feb 21, 2020

Dr. Mike Dudley (@MikeMndudley), President and CEO of Qpex Biopharma, joins Dr. Erin McCreary (@erinmccreary) to discuss the thrills and failures of antibiotic discovery and development along with the critical need for antibiotic market reform. We discuss the complexity of antibiotic resistance in gram-negative pathogens, antibiotic targets, potential market solutions, and more!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#18 – Waking the Sleeping Giant: Engaging Nurses in Antimicrobial Stewardship Jan 17, 2020

Dr. David Ha (@DHpharmd) interviews Dr. Rita Olans (@RitaOlans) and Dr. Elizabeth Monsees (@eamonsees) about the critical role nurses play in antimicrobial stewardship. They discuss how nursing practice overlaps with stewardship teams, case examples of nurse integration in stewardship in various practice settings, guidance documents, and real-world advice for advancing your stewardship services with nursing collaboration.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#17 – See C. diff: A Discussion on Patient Advocacy Dec 20, 2019

Christian John Lillis, co-founder and Executive Director of the Peggy Lillis Foundation (@peggyfund), joins Erin McCreary (@erinmccreary) to share his mother’s story and discuss opportunities and challenges for patient advocacy and antimicrobial resistance.

Get involved with the Peggy Lillis Foundation: https://peggyfoundation.org/get-involved/take-action/

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#16 – 5 Ways Hospital Pharmacists Can Be Antibiotics Aware Nov 20, 2019

Dr. Susan Davis (@IDPharmProf) and Dr. Jason Pogue (@jpogue1) celebrate Antibiotic Awareness Week by discussing the 5 Ways Hospital Pharmacists Can Be Antibiotics Aware, including: verify penicillin allergy, avoid duplicate anaerobic coverage, reassess antibiotic therapy, avoid treatment of asymptomatic bacteriuria, use the shortest effective antibiotic duration.

CDC Poster: https://www.cdc.gov/antibiotic-use/community/pdfs/Hospital-Pharmacist-Poster-508.pdf

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#15 – CDC Core Elements of Hospital Antibiotic Stewardship Programs: 2019 Update Nov 18, 2019

Dr. Arjun Srinivasan and Dr. Melinda Neuhauser join host Dr. Erin McCreary (@erinmccreary) to discuss the updated Core Elements of Hospital Antibiotic Stewardship Programs from the Centers for Disease Control and Prevention. These updates emphasize the importance of pharmacist and physician co-led stewardship programs and expanding the stewardship team to all hospital groups and departments.

CDC Core Elements 2019: https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-H.pdf

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#14 – Pumpkin-Spiced Lessons: Phages, Posters, and Paul Sax Nov 08, 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) are joined by Dr. Paul Sax (@PaulSaxMD) to review important updates in HIV care from IDWeek 2019. They also go “rapid fire” through posters and oral abstracts presented at IDWeek 2019, nerd out over genomics, phages, and beta-lactamases, and discuss the new CAP and vancomycin guidelines.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#13 – Provocative Titles and Pro-Con Debates Nov 08, 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) discuss the IDWeek 2019 session "We're Part of the Problem: How ID Killed Antibiotic Development' and other hot topics including pro-con debates, behavioral approaches to antimicrobial stewardship, and more.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#12 – Late Breaker Trials and #WhyIVaccinate Nov 01, 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) share some big announcements from IDWeek 2019 including the #WhyIVaccinate movement, data from late-breaking clinical trials, new partnerships, and more!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#11 – Practice-changing Publications ft. David van Duin Nov 01, 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) are joined by Dr. David van Duin (@davidvanduin) to review “Clinical Trials That Might Change Your Practice” in bacteriology, virology, and mycology from IDWeek 2019.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#10 – So You're an Antimicrobial Steward... Now What? Jul 31, 2019

Host Erin McCreary (@erinmccreary) and expert panelists Libby Dodds Ashley (@The_Real_LDA), Lisa Dumkow (@LisaIDpharmD), and Jamie Kisgen (@KisgenUF) share real-world experiences in order to empower new (and existing) practitioners as antimicrobial stewardship leaders. Find out how to get started based on different training and work environments, develop relationships with key players, and address the importance of “big picture” goal setting within stewardship programs. Listen and learn (and get ready for some great stories!)

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#9 – Show Me the Data! Jul 31, 2019

Host Erin McCreary (@erinmccreary) and expert panelists Libby Dodds Ashley (@The_Real_LDA), Lisa Dumkow (@LisaIDpharmD), and Jamie Kisgen (@KisgenUF) discuss how to market your stewardship program, with an emphasis on generating meaningful data to sustain and expand your program. Panelists share how they balance day-to-day activities with moving big projects forward, leveraging learners, presenting to the C-suite, and more.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#8 – Stewardship is a Team Sport Jul 31, 2019

Journey with host Erin McCreary (@erinmccreary) and expert panelists Libby Dodds Ashley (@The_Real_LDA), Lisa Dumkow (@LisaIDpharmD), and Jamie Kisgen (@KisgenUF) through their lessons learned and favorite moments of their stewardship careers. We describe how to evolve as a stewardship team member and leader, enhance collaborations, promote culture change, and give and receive feedback.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#7 – Rapid Fire Data from ECCMID 2019 Jul 10, 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) go “rapid fire” through posters and oral abstracts presented at ECCMID 2019, including: rapid diagnostics, the influence of leadership in antimicrobial stewardship, iPad technology and patient’s beliefs about antibiotics, imipenem-relebactam, cefiderocol, rezafungin, ibrexafungerp, sulbactam-ETX2514, iclaprim, lefamulin, and tebipenem.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#6 – Tazobactam and Tulips: Hot Topics from ECCMID 2019 Jul 10, 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review expanded MERINO trial data including mortality by pathogen MIC, PK-PD principles, BLING III, beta-lactam therapeutic drug monitoring, linezolid dosing in renal impairment, microbiology issues, and updates from EUCAST.

CORRECTION: Piperacillin-tazobactam was dosed 4.5g IV every 6 hours in the Merino trial.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#5 – Nerding Out at ECCMID 2019 Jul 10, 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) share their secret passions and nerdiest moments from ECCMID 2019, including multi-omics data for Pseudomonas aeruginosa, the effects of chemotherapy on antimicrobial resistance, phage therapy, and more!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#4 – How ECCMID 2019 went viral Jul 10, 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review results of ASPECT-NP (Ceftolozane-tazobactam versus meropenem in patients with ventilated nosocomial pneumonia), CAMERA-2 (Combination therapy for methicillin-resistant Staphylococcus aureus bacteraemia), and Exebacase for patients with methicillin-resistant Staphylococcus aureus bacteraemia (Phase 2).

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

#3 – Lessons Learned From the Front Line Jun 26, 2019

In the final part of our three part series on penicillin allergies host Jason Pogue (@jpogue1) and our expert panelists Julie Ann Justo (@julie_justo), Bruce Jones (@Bruce_M_Jones), and Mary Staicu (@marylynnstaicu) discuss important clinical pearls and lessons learned from the front line that can be helpful for those interested in starting a penicillin allergy program. The panel then wraps up by discussing future directions for penicillin allergy management.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

This podcast is powered by Pinecast.

#2 – Implementing Penicillin Skin Testing Jun 26, 2019

In episode 2 host Jason Pogue (@jpogue1) and panelists Julie Ann Justo (@julie_justo), Bruce Jones (@Bruce_M_Jones), and Mary Staicu (@marylynnstaicu) discuss strategies for allergy reconciliation and implementation of penicillin skin testing. They discuss their experience with different penicillin skin testing models and how their institution landed on those models. They also describe what factors should be taken into consideration in order to determine which model works best for your institution, and what resources are available to get you started.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

This podcast is powered by Pinecast.

#1 – Mythbusting Jun 26, 2019

In this episode host Jason Pogue (@jpogue1) discusses common misconceptions surrounding penicillin allergies, provides evidence to dispute these misgivings, and describes some of the consequences that arise from an inappropriate penicillin allergy label for a patient with expert panelists Julie Ann Justo (@julie_justo), Bruce Jones (@Bruce_M_Jones), and Mary Staicu (@marylynnstaicu).

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

This podcast is powered by Pinecast.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Breakpoints

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Episode Notes

Related Podcasts

Links

Stay Connected